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The human cystathionine β-synthase (CBS) is a 5’ pyridoxal phosphate (PLP) 
dependent protein that catalyzes the condensation reaction between serine and 
homocysteine to yield cystathionine. This is the first step in the transsulfuration pathway 
which connects the methionine cycle to cysteine production. Mutations in CBS are the 
single most common cause of severe hereditary hyperhomocystenemia and over one 
hundred pathogenic mutations have been described so far. These mutations represent 
residues which are important for the structural and functional integrity of the enzyme. 
The biochemical characterization of these mutants thus leads to further insights into 
structure-function correlations in CBS.  
CBS has a subunit mass of 63 kDa and is a modular protein with 551 amino acids. 
The N-terminal half of the protein houses the two cofactors, PLP and heme and a CXXC 
motif comprised of residues C272 P273, G274 and C275. This motif is also found in the 
thioredoxin family of proteins where it is involved in thiol disulfide exchange reactions. 
The heme, which is coordinated by the axial ligands H65 and C52, is about 20 Å away 
from the CXXC motif as well as the PLP catalytic center. As such, heme does not 
contribute directly to catalysis, but is believed to be a center for redox regulation in CBS.  
The C-terminal half of the protein comprising residues 413 to 551 bear  a tandem 
repeat of “CBS domains,” which are secondary structural motifs found in diverse families 
of proteins with no sequence similarities. In CBS, these domains are believed to be 
involved in the binding of the allosteric activator S-adenosyl methionine (AdoMet). 
Along with being involved in allosteric regulation, the C-terminal domain of CBS 
imposes intrasteric regulation on the catalytic core. Thus deletion of the C-terminal 
regulatory domain leads to the formation of a super-active enzyme, CBS-ΔC143 which 
has a 4-fold higher kcat than the full-length protein. It is also known that a truncated form 
of CBS is generated in cells exposed to proinflamatory agents such as TNFα. Although 
this observation suggests that the C-terminal domain interacts with the N-terminal 
catalytic core to effect this regulation, so far no experimental results were available which 
would characterize the nature of this interaction. In other words no information was 
available regarding the conformational changes associated with the allosteric and 
intrasteric regulation in CBS.  
In this study, we have mapped the regions of intrasteric and allosteric regulation in 
CBS. We have employed hydrogen/deuterium (H/D) exchange, mass spectrometric 
technique to locate conformational changes in the enzyme upon the binding of its 
allosteric activator, AdoMet. We have also used this approach to detect the surface 
involved in the interaction of the C-terminal domain with the catalytic core relevant to 
intrasteric regulation. A change in the kinetics of H/D exchange was located in a single 
peptide, extending from residues 511-531 upon AdoMet binding. CBS-D444N a patient 
mutant exhibits a similar change in the above peptide in its native state and thus samples 
a conformation which is acquired by the wild type upon AdoMet binding. Accordingly 
this mutant is not responsive to any further activation by the allosteric activator. Peptides 
356-370 and 371-385 in the N-terminal half of the protein exhibited a change in H/D 
exchange kinetics when the full-length and its counter part in CBS-ΔC143, were 
compared by H/D exchange studies, associating this region with intrasteric regulation. 
We have also demonstrated that in addition to heme, the CXXC motif in CBS is a center 
for redox regulation. Thiol alkylation followed by mass spectrometric analysis 
demonstrated formation of an intramolecular disulfide bridge between C272 and C275, 
and identified the presence of a sulfenic acid intermediate under air oxidized conditions 
in CBS-ΔC143. The full length and the CBS-ΔC143 enzyme exhibited a 1.6 and 4.5 fold 
enhancement in specific activity respectively upon reduction of their disulfides at the 
CXXC center. A redox potential of -240 ± 4 mV was determined for the CXXC center 
using MAL-PEG for titrating thiol content at various ratios of oxidized and reduced 
dithiotreitol.  
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Chapter1 
Introduction 
2 
1.1 Toxicity of homocysteine 
Homocysteine is a non protein sulfur containing amino acid formed during the 
metabolism of an essential amino acid methionine. Carson and Neil independently 
described the first error in methionine metabolism by demonstrating an excessive urinary 
excretion of homocysteine in children who had a deficiency in CBS activity (5). 
Following this, it was also reported that children with homocystinuria, an autosomal 
recessive condition  showed signs of cardioavascular disorders (35). This lead Dr. Kilmer 
Mc Cully to suggest a correlation between high levels of homocysteine and 
cardiovascular diseases (26, 35). Studies over the last twenty-five years have shown that 
even, mild elevation of homocysteine in the plasma is an independent risk factor for 
occlusive arterial disease, venous thrombis and vascular causes of mortality (26). More 
than fifty percent of patients with stroke and/or other cardiovascular diseases have 
homocysteine levels outside the normal range, which is around 10-15 µM for men and 6-
10 µM for women. High levels of homocysteine, are also correlated with several other 
diseases such as neural tube defects and Alzheimer’s diseases (20, 36). 
 
 
1.2 Role of cystathionine β-synthase in metabolism 
Cystathionine β-synthase [EC 4.2.1.22: CBS], is a heme protein and catalyzes the 
pyridoxal 5’- phosphate (PLP)-dependent condensation of serine and homocysteine to 
form cystathionine (63). CBS catalyzes the only reaction that irreversibly removes the 
toxic metabolite, homocysteine, from the methionine cycle.  This is followed by the 
action of a second PLP dependent enzyme, cystathionine γ-lyase which catalyzes the 
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hydrolysis of cystathionine to α-ketoglutarate and cysteine, a precursor of the major 
cellular redox buffer, glutathione. Thus CBS catalyzes the first committed step in the 
transulfuration pathway. Homocysteine, a non-protein sulfur containing amino acid 
occupies a key biochemical intersection in the methionine cycle between S-adenosyl 
methionine (AdoMet), the indispensable and ubiquitous methyl group donor in various 
biological reactions. Homocysteine metabolism is thus regulated to strike a balance 
between the methylation and transulfuration pathways and to maintain low levels of this 
toxic metabolite (13). 
 
 
1.3 Regulation and homocysteine metabolism 
Homocysteine is an intermediate in methionine metabolism and is cleared via one of 
two pathways: the remethylation pathway which regenerates methionine by transfer of a 
methyl group to homocysteine, and the transsulfuration pathway that degrades 
homocysteine into cysteine (Fig1.1). Remethylation of homocysteine to methionine is 
catalyzed by one of two zinc enzymes, cobalamin–dependent methionine synthase (MS) 
and betaine homocysteine methyl transferase. Another important enzyme in the 
remethylation pathway is methylenetetrahydrofolate reductase (MTHFR) that generates 
methyl tetrahydrofolate, the methyl group donor for the methionine synthase–catalyzed 
reaction. Although both MS and betaine homocysteine methyl transferase, catalyze the 
remethylation of homocysteine betaine homocysteine methyl transferase has limited 
tissue distribution being present mainly in the liver and kidneys (19), whereas MS is 
ubiquitous. 
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AdoMet, a ubiquitous methyl donor in various metabolic reactions including RNA, 
DNA, lipid and protein methylations and a precursor of polyamines, is synthesized by 
adenosylation of methionine catalyzed by methionine adenosyltransferase. AdoMet is 
demethylated by a variety of methyl transferases to give S-adenosyl homocysteine, which 
in turn is hydrolyzed to give adenosine and homocysteine catalyzed by S-adenosyl 
homocysteine hydrolase. 
Homocysteine is at a branch point in methionine metabolism. In liver cells, 
approximately half of the total homocysteine formed is remethylated back to methionine 
and half is committed to the transsulfuration pathway (16) for the synthesis of cysteine. 
The transulfuration pathway also provides a route for the disposal of excess sulfur via 
cysteine catabolism. The flux of homocysteine through the complex pathways is tightly 
regulated. One regulatory switch between methionine cycle and transulfuration pathway 
is AdoMet (14). At high concentrations of AdoMet, remethylation of homocsyteine to 
methionine is inhibited (15, 60). High concentrations of AdoMet signal methionine 
sufficiency and represses remethylation by inhibiting MTHFR, the source of methyl 
tetrahydrofolate, the methyl donor in the reaction catalyzed by methionine synthase. 
Under the same conditions, CBS is activated by AdoMet which increases flux of 
homocysteine through the transulfuration pathway. It is estimated that ~ 50% of cysteine 
in the intracellular glutathione pool is derived from homocysteine via the transulfuration 
pathway in liver cells (43, 61). Thus, regulation at the level of CBS directly controls the 
removal of homocysteine from the methionine cycle, thereby influencing glutathione-
based redox homeostasis. 
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Figure1.1. An overview of homocysteine metabolism. 
 
 
 
Enzymes involved in methionine metabolism cycle are also regulated by the redox status 
of the cell. AdoMet synthesis from methionine has been shown to be responsive to 
oxidative stress. The two isoforms of methionine adenosyltransferase that catalyze 
AdoMet synthesis are down-regulated under oxidative stress conditions marked by a low 
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GSH/GSSG ratio. This inhibition is reversed with GSH (48, 50). MS and CBS, the two 
enzymes which use homocysteine as a substrate,  both contain  redox active cofactors and 
are reciprocally sensitive to oxidative stress providing an additional level of regulation 
for switching  between  the methionine cycle and  the transulfuration pathway (7, 56). 
Under oxidative conditions MS is inhibited due to the oxidation of its cofactor 
cob(I)calamine to cob(II)calamine and by the possible oxidative modification of the 
cysteine ligands to the active site zinc (7). In CBS however, redox regulation is 
potentially complicated and occurs at two centers in the enzyme. Studies in our 
laboratory have shown that the reduction of the heme in CBS leads to an approximately 
2-fold diminution in its specific activity (56). On the other hand, reduction of the 
disulfide bridge in the CXXC motif enhances its activity (Sen S, Banerjee R, unpublished 
data). The opposing redox regulation by the heme and the CXXC motif of CBS activity 
suggests that it is most active when the CXXC motif is reduced and the heme is oxidized 
and least active when both redox centers are either fully reduced or fully oxidized.  
Addition of H2O2 or tertiarybutyl hydroperoxide to cultured human liver cells induces 
oxidative stress leading to a 2-3 fold increase in the flux of homocysteine through the 
transulfuration pathway (43). Another mechanism for oxidative activation of CBS is the 
targeted endoproteolysis to generate the truncated dimer. This is observed under some 
conditions, e.g. when the cytokines TNFα is added to cultured human cells (65). Under 
these conditions AdoMet activation is lost consistent with the cleavage of the C-terminal 
regulatory domain. In vitro truncated CBS has four-fold higher kcat than full length CBS 
and is not regulated by the allosteric activator AdoMet (57). TNFα induced targeted 
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proteolysis of CBS is inhibited by scavengers of superoxide production or by the 
overexpression of manganese superoxide dismutase (65).  
 
 
1.4 Impairments in homocysteine metabolism and disease 
High levels of homocysteine have been correlated with various diseases affecting the 
cardiovascular, neural, ocular and skeletal organ systems. Mutations in CBS or in MS, 
the two most prevalent homocysteine-utilizing enzymes, or perturbations in their 
regulatory systems, lead to elevated levels of plasma homocysteine. Further mutations in 
homocysteine utilizing enzymes, or perturbations in their regulatory systems are the most 
common cause of elevated levels of plasma homocysteine. Further mutations in 
methyltetrahydrofolate reductase, which indirectly affects homocysteine clearance is also 
associated with homocystinurea as are mutations in MS reductase an enzyme required for 
regulation of active MS (58),(59). Elevated levels of homocysteine can also result from a 
diet poor in vitamins as many enzymes involved in this pathway utilizes vitamins such as 
folic acid, cobalamin (B12) and PLP (B6) as their cofactors. High levels of homocysteine 
are accompanied by high levels of AdoHcy, which is a potent inhibitor of AdoMet–
dependent methylation reactions (10), (21). CBS deficiency impairs flux through the 
transulfuration pathway and leads to defects in sulfur metabolism including glutathione 
biosynthesis. In healthy individuals, plasma homocysteine levels range from 10-15 µM. 
Concentrations ranging from 15-100µM and > 100 µM are classified as moderate 
hyperhomocysteinemia and severe hyperhomocysteinemia respectively (38), (37).  
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Severe hyperhomocysteinemia, an inherited autosomal metabolic disorder, is 
characterized biochemically by high levels of homocysteine in the plasma and in the 
urine (39). CBS deficiency is the most common cause of hereditary 
hyperhomocysteinemia (45). Clinically, this disease is characterized by thrombosis, 
mental retardation, premature artherosclerosis, connective tissue disorders including 
osteoporosis, lens dislocation and skeletal abnormalities resembling Marfan syndrome 
with long thin extremities, decreased upper/lower segment ratio and arachnodactyly (44). 
Studies showed that about 30% of homocystinuric patients experience stroke or heart 
attack by the age of 20 (45).  
Hyperhomocysteinemia due to CBS deficiency is distinct from other defects leading 
to homocystinurea. Connective tissue disorders are also associated with CBS deficiency 
(9).  
 
 
1.5 CBS gene map  
The CBS gene maps to the subtelomeric region of the human chromosome 21 
(21q22.3) (37, 38) and contains 23 exons, spanning a region of 30 Kb. The CBS 
polypeptide has 551 amino acids and is encoded by exons 1 through 14 and exons 16. 
Exon 15 is alternatively spliced and is detected only rarely in mature mRNA molecules. 
The 14 amino acids encoded by this exon have not been detected in the CBS polypeptide 
from various mammalian tissues (33), (31). The 5’ UTR of human CBS is encoded by 
one of five alternatively used exons, -1a b, c, d, e, and exon o present in the CBS gene. 
The 3’UTR is encoded by exons 16 and 17 (33). A polymorphism found in 5% of normal 
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Caucasian alleles has been described in which exon 8 has a 68 bp fragment insertion, 
8444ins68 that is spliced out from the mature mRNA (52). 
 
 
1.6 Structural and functional properties of the human CBS 
Human cystathionine β-synthase (CBS), a key enzyme in sulfur metabolism, 
catalyzes the condensation reaction of homocysteine and serine to yield cystathionine 
(Scheme 1). This is the first of two PLP-dependent steps in the transulfuration pathway 
which converts methionine to cysteine. 
 
 
 
Scheme 1. Schematic representation of the reaction catalyzed by CBS. 
 
 
 
The cysteine formed is used for multiple purposes including the synthesis of glutathione 
which is present at high concentrations and is involved in maintaining cellular redox 
balance. Under conditions of oxidative stress, the flux of sulfur through the 
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transulfuration pathway increases resulting in a concomitant rise in glutathione synthesis 
(41).  
CBS is a unique PLP- dependent enzyme in that it is also heme dependent. The 
enzyme exists as a tetramer and a mixture of higher oligomers ranging from a dimer to a 
16- mar (17). The subunit molecular weight is ~63 kDa. Each subunit binds one heme 
and one PLP. The V–type allosteric activator AdoMet binds stoichiometrically to each 
subunit and increases the activity of the enzyme by 2- to 3- fold (34). 
CBS is a modular protein, the N-terminal domain of which houses the heme and PLP 
cofactors along with a -CPGC- motif commonly found in the active sites of thioredoxin 
family of proteins involved in thiol disulfide exchange reactions (22). The C-terminal 
domain comprises the regulatory third of the protein and houses a tandem repeat of “CBS 
domains”, a β-α-β-β-α secondary structure motif found in a variety of unrelated proteins 
in all three kingdoms of life (2). AdoMet, the allosteric activator is believed to bind to the 
CBS domains (51).  
Crystal structure of the truncated dimer of CBS 
The crystal structure of a truncated dimeric form of human CBS, lacking the 
regulatory domain (413-551) has been solved (Fig 1.2) (24), (55). The fold of the 
truncated human CBS enzyme belongs to the β-family of vitamin B6 enzymes (1) and 
resembles the fold found in O-acetyl-serine sulfhydrylase from Salmonella typhimurium 
(4).  
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Fig 1.2. Ribbon representation of the crystal structure of the truncated dimer of CBS.  
 
 
 
Three other PLP enzymes whose structures are known share the same fold type: 
tryptophan synthase (23), threonine demainase (18) and aminocyclopropane deaminase 
(64). A least square superposition of the Cα-positions of the structurally conserved parts 
between CBS and O-acetyl-serine sulfhydrylase yields a root mean square deviation of 
only 1.32 Å with the differences between the structures being mainly located in the loop 
regions.  
The CBS monomer is composed of 11 α helices, seven short 310 helices and two β-
sheets consisting of four and six strands in the N-terminal and C-terminal domains 
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respectively.  The heme binding domain is largely unstructured with the exception of a 
short 310 α-helix. The dimer interface is highly hydrophobic in character. The central part 
of the dimer interface is formed by residues F 111 and F112 close to the 2-fold dimer 
axis. F 112 of one monomer thus interacts with F112 of the other. Although hydrophobic 
interactions dominate at the interface, polar interactions also contribute to dimer 
formation.  PLP is deeply buried in a cleft between the N-terminal third and the C-
terminal regulatory domain. The active site is accessible only by a narrow channel. The 
cofactor is linked to the ε-amino group of K119 via a Schiff base linkage forming the 
internal aldimine. The nitrogen of the pyridine ring forms a hydrogen bond to the Oγ of 
Ser349 similar to the other enzymes of β-family of PLP enzymes. A second hydrogen 
bond is formed between the 3’ hydroxyl group of PLP and the Nδ2 of Asn149. This 
residue is coplanar with the pyridine ring and thus allows the expected ring tilt upon 
transaldimination. The phosphate binding groups Gly256, T257, G258, G259 and T260 
form extended hydrogen bonds with the phosphate moiety of the PLP anchoring the 
cofactor to the protein matrix. Residues Y223 and G307 are probably key residues for 
substrate specificity, as they are spatially adjacent to the inferred substrate binding site.  
The heme in CBS 
Each dimer contains two hemes located at distal ends of the dimers with the 
orientation of their planes normal to the plane of the protein. The heme spectrum of CBS 
analyzed by the pyridine hemechrome method is typical of iron protophorphyrin IX (61). 
Ferric CBS, as isolated, exhibits a Soret absorption maximum at 428 nm and a broad αβ-
band centered at ~550 nm, which is typical of low-spin 6- coordinate heme. The heme is 
bound in a hydrophobic pocket formed by residues 50-67, α-helices 6 and 8 and a loop 
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preceding β-strand 10. The sulfhydryl group of C52 and the Nε2 atom of H65 coordinate 
the heme axially. The sulfur atom of C52 is believed to be deprotonated (12) and engages 
in additional interactions with the side chain of R266 and the main chain nitrogen of 
W54. The carboxylate groups of heme are involved in ionic interactions with R51 and 
R224 and are partially solvent exposed unlike in cytochrome c peroxidase and 
cytochrome P450 iron, where the heme is buried in an internal cavity in the protein (40). 
Since the iron ion is ligated from both sides by protein residues and that the heme is 
located almost ~20 Å away from the active site, it rules out a catalytic role for heme. 
Carbon monoxide binds to the ferrous heme displacing the thiolate ligand (57). The 
enzyme retains 25% of activity under such conditions (3). Reduction of the heme from +3 
to +2 oxidation state is correlated with a decrease in enzyme activity by ~1.5 fold under 
in vitro assay conditions. The Soret peak at 428 undergoes a red-shift to 450 nm under 
reduction of the heme with titanium citrate or dithionite (56), (46) with a concomitant 
sharpening of the αβ- bands at 540 and 571 respectively. A midpoint potential of -350 
mV has been measured for the heme in full length CBS and -287 mV in the truncated 
variant (Madzelan P, Banerjee R, unpublished results). Ferric CBS shows a bell shaped 
pH dependence on enzyme activity with pKa1 and pKa2 values of 7.9 ± 0.2 and 8.8 ± 0.2 
respectively (56). The electronic absorption spectrum of ferric CBS is independent of pH 
in the range 6-9 (8), indicating that a change in the heme environment is not related to the 
kinetic pKas. The properties of the ferrous heme however are affected by both pH and 
temperature (8).  
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The CXXC motif in CBS 
Residues 272 through 275 comprise the CXXC motif in CBS. In the crystal structure, 
the loop between α-helix 8 and β-strand 9 harbors this motif and is similar to that seen in 
active sites of disulfide oxidoreductases. The consensus sequence in this motif in 
oxidoreductases contains two cysteines that are linked by two residues one of which is 
proline (Table 1).  
Human     -KCPGCR-
Monkey    -KCPGCR-
Rat           -KCPGCK-
Mouse      -KCPGCK-
Frog         -KCPNCK-
C275C272    
 
Table 1. Sequence alignment of the CXXC motif. 
 
 
 
The CXXC motif in oxidoreductases is involved in various redox reactions in the cell, 
because they can be reversibly oxidized and reduced by switching between a disulfide 
and dithiol form during a catalytic process. In CBS, this motif consists of CPGC and 
forms a β turn. In the two crystal structures of truncated CBS (55), the CXXC motif is 
seen in both the disulfide bridge and the dithiol forms. The structure of glutaredoxin from 
Escherichia coli can be superimposed onto CBS. In this superimposition, α-helix 1 of 
glutaredoxin merges onto α-helix 7 of CBS, and α-helix 3 onto α-helix 8 of CBS albeit 
in opposite directions (55). The four strands of the central β-sheet of glutaredoxin fit onto 
strands 3, 8, 9 and 11 of the C-terminal domain of CBS. In CBS, the CXXC motif is 
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found at a location corresponding to the N-terminal end of α-helix 3 of glutaredoxin, 
while in glutaredoxin it is located at the N-terminal end of α-helix 1 (55). Thus, in 
addition to heme, the CXXC motif is another redox-active center in CBS.  
 
 
1.7 Intrasteric and Allosteric Regulation in CBS 
Purification of the wild-type enzyme from mammalian liver has resulted in the 
isolation of mixtures of the full-length as well as truncated but active dimeric forms of 
the enzyme (30). Limited proteolysis also yields a 45 kDa subunit and is accompanied by 
a change in the oligomeric state representing a dimer. This form of the enzyme 
represented the catalytic core and extends from amino acids 31, 37, or 40 through 413 
and exhibits a kcat which is 4-fold more than the full-length enzyme. The N-terminus of 
this polypeptide is heterogeneous due to multiple susceptible proteolytic sites at lysines 
30, 36 and 39. Alternatively the catalytic-core can be generated by introduction of an opal 
mutation at position 409 in the open reading frame and the resulting protein extends from 
residues 1 to 408 (CBS-ΔC143) (54). The activity of this variant, was higher than that of 
the full-length (27). A truncated variant is also formed upon TNFα exposure in liver cells 
(65). The latter was also shown to be more active than the full-length enzyme and lacked 
allosteric regulation (57). Together these observations showed that the C-terminal 
regulatory domain imposes intrasteric regulation on the catalytic core. AdoMet which is 
believed to bind to the C-terminal domain of the full-length enzyme relieves this 
intrasteric inhibition. Binding of AdoMet increases the Kcat of the full length enzyme ~2 
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to ~3 fold, while truncation beyond the catalytic core increases kcat ~4 fold compared to 
the basal activity associated with the full-length enzyme (57).  
A patient mutation D444N located in the C-terminal domain, is highly active but is 
insensitive to allosteric regulation at physiological concentrations of AdoMet (11). 
Another interesting patient mutation P78R/K102N in the N-terminal catalytic core of the 
protein has recently been shown to be unresponsive to AdoMet (53). These observations 
suggest that there exists a significant amount of interaction between the catalytic core and 
the regulatory C-terminal domain. When this inter domain interaction is compromised as 
in the above mutants they are rendered unresponsive to AdoMet. In addition to allosteric 
regulation, binding of AdoMet to CBS also modulates the stability of the protein. The 
half life of CBS in liver cells increases from 18 to 49 h in the presence of AdoMet (49). 
 
 
1.8 Mutations in CBS 
Mutations in CBS are the most common cause of severe hereditary 
hyperhomocysteinemia (29). The vast majority of the mutations are missense with the 
remainder being nonsense, deletion and insertion mutations (32),(42). Characterization of 
patient mutations could lead to a better understanding of structural-functional correlations 
in CBS. Over 130 pathogenic mutations have been described that are spread over the 
coding and intronic sequences of the gene. The biochemical penalties associated with 
some of the pathogenic mutants have been addressed but the majority remains 
uncharacterized due to lack of a full-length crystal structure of the protein along with 
difficulties associated with the purification of many of the mutants which tend to form 
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aggregates (6), (25), (47). The two most common mutations in CBS are I278T and 
G307S found in an Italyan population (28). CBS mutants may or may not respond to 
PLP. Mutations in CBS are distributed along the whole length of the protein affecting 
various structural properties depending on their localization. Some such P78R, R379Q 
and E176K missense mutations localize to the dimer interface. Others are predicted to be 
at the interface between the regulatory domain and the catalytic core (62). The S466L and 
D444N mutations map on the CBS1 domain on the regulatory domain and the mutant 
proteins do not respond to the allosteric activator AdoMet as the “CBS domains” are said 
to be involved in nucleotide binding (62). A GST fusion of the isolated CBS domain pair 
(residues 416-551) from CBS was shown to bind AdoMet with a Kd   of 34 µM  while the 
D444N mutant increased the Kd by 15-fold to 510 µM (51). 
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Chapter 2 
Mapping Peptides Correlated with Transmission of Intrasteric Inhibition and 
Allosteric Activation in Human Cystathionine β-Synthase 
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2.1 ABSTRACT 
Cystathionine β-synthase plays a key role in the intracellular disposal of 
homocysteine and is the single most common locus of mutations associated with 
homocystinuria. Elevated levels of homocysteine are correlated with heart disease, 
Alzheimer’s and Parkinson’s diseases, and neural tube defects. Cystathionine β-synthase 
is modular and subjected to complex regulation, but insights into the structural basis of 
this regulation are lacking. We have employed hydrogen exchange mass spectrometry to 
map peptides whose motions are correlated with transmission of intrasteric inhibition and 
allosteric activation. The mass spectrometric data provide an excellent correlation 
between kinetically and conformationally distinguishable states of the enzyme. We also 
demonstrate that a pathogenic regulatory domain mutant, D444N, is conformationally 
locked in one of two states sampled by the wild type enzyme. Our hydrogen exchange 
data identify surfaces that are potentially involved in the juxtaposition of the regulatory 
and catalytic domains and form the basis of a docked structural model for the full-length 
enzyme.  
 
 
2.2 Introduction 
Equilibration between different conformational states often poses problems for 
crystallization of modular proteins, thus limiting access to structural information. 
Hydrogen exchange mass spectrometry is a powerful approach that can partially 
circumvent this limitation. Thus, motions that are correlated with interconversion 
between conformational states or with transduction of signals from sites distal to active 
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sites can be localized (1, 2). Human cystathionine β-synthase is an example of a modular 
protein that catalyzes the condensation of homocysteine and serine to give cystathionine. 
This represents the first step in the transsulfuration pathway that connects the methionine 
cycle to cysteine production and also provides an avenue for disposal of sulfur under 
conditions of excess (3, 4). The structure of a truncated catalytic core (5, 6) but not of the 
full-length protein is available, limiting structural insights into the dynamics that underlie 
exertion of the complex regulation associated with this enzyme. Cystathionine β-synthase 
is unique in being a PLP-dependent enzyme that also contains a heme b cofactor of 
unknown function (7). In this enzyme, a central catalytic core houses the active site and is 
interposed between an N-terminal heme domain and a C-terminal regulatory domain 
(Figure 1) (3, 4). The regulatory domain per se exerts intrasteric control over the catalytic 
module and its deletion results in an active form of the enzyme that displays a 4-fold 
higher kcat but is unresponsive to the allosteric effector, S-adenosylmethionine (AdoMet)
 
(8, 9).The regulatory domain is also important in the oligomeric architecture of the 
protein, and its deletion converts the native tetrameric (α4) enzyme to a dimeric (α2) 
form. This transformation from the full-length to the truncated form lacking the 
regulatory domain is observed in cells treated with the cytokine, TNFR, or in mice 
challenged with the proinflammatory agent, lipopolysaccharide (10). A more modest 
activation of the enzyme is observed with AdoMet, a V-type allosteric effector, which 
enhances kcat ~ 2-fold (8) and is presumed to bind to the regulatory domain (11).  
Mutations in cystathionine β-synthase are the single most common cause of 
homocystinuria and over 100 disease-associated mutations have been identified in 
patients (12). A subset of these pathogenic mutations maps to the regulatory domain 
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appears to impose a conformational lock on the protein and is unresponsive to AdoMet 
(13, 14). While the structure of the N-terminal catalytic core of cystathionine β-synthase 
has been determined (5, 6), no structural information is available for the regulatory 
domain, where the allosteric activator is presumed to bind (11). In this study, we have 
employed hydrogen exchange mass spectrometry (MS) to identify peptides that respond 
 
 
 
Figure 1. Modular organization and kinetic forms of human cystathionine β-synthase. 
A. The domains in human cystathionine β-synthase include an N-terminal heme domain, 
a central catalytic core and a C-terminal regulatory domain containing a tandem repeat of 
two CBS domains. B. Kinetically distinguishable states of human cystathionine β-
synthase. A, P, and H denote AdoMet, PLP, and heme, respectively. 
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to the presence of AdoMet and those that respond to deletion of the regulatory domain, to 
locate regions associated with intrasteric inhibition and allosteric activation, respectively.  
 
 
2.3 Experimental Section 
Materials. Deuterium oxide (100.00 atom % D) was purchased from Sigma. Pepsin (from 
porcine stomach mucosa), and protease inhibitors were purchased from Sigma,porcine 
trypsin was from Promega and thrombin (bovine) was purchased from GenTrac Inc. 
Middleton, WI. 
Enzyme Purification. Wild-type enzyme, the C-terminal truncated form (designated 
ΔC143), and the D444N mutant were expressed and purified as previously described (8, 
14, 15). 
Limited Proteolysis of Cystathionine β-Synthase. Cystathionine β-synthase was subjected 
to limited proteolysis as described in the Figure 2 caption and quenched at the desired 
times with Nα-p-tosyl-L lysine chloromethyl ketone (Sigma). 
Hydrogen-Deuterium Exchange. The feasibility of the H/D exchange MS method was 
initially assessed for cystathionine β-synthase by determining the sequence coverage and 
the spectral quality of its peptides. For this, cystathionine β-synthase (10 μg) in 100 mM 
ammonium phosphate buffer, pH 2.2, was centrifuged to remove any insoluble matter 
and digested with pepsin (1:1 w/w) for 5 min on ice. The peptic fragments were separated 
by HPLC and identified by tandem ESI-MS/MS as described below. Approximately 76% 
sequence coverage was obtained (Table 1 and Figure 2). One of the major peptides that 
was not observed in this analysis extends from residues 252-287 and resides in a protease 
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resistant core of the protein (16). Additionally, the peptides in the N-terminal heme 
domain were not detected, which could have resulted from a paucity of pepsin cleavage 
sites in this region. The mutant enzymes, ΔC143 and D444N (10 μg and 20 μg 
respectively) in 10 mM phosphate buffer, pH 6.8, were diluted 20-fold in the exchange 
buffer prepared in D2O (10 mM phosphate buffer, pD 6.8). For samples containing 
cystathionine β-synthase complexed with AdoMet, the enzyme was preincubated with 1 
mM AdoMet at room temperature for 2 h. For H/D exchange studies, samples were 
incubated at room temperature for 5 to 60 s (to determine the effect of AdoMet) or 
between 5 s and 21 h (to monitor the kinetics of hydrogen exchange in full-length 
enzyme and the truncated variant, ΔC143) and quenched by a 2-fold dilution with 100 
mM ammonium phosphate buffer, pH 2.2. The quenched samples were immediately 
frozen in liquid nitrogen and stored at -80 °C until further use. Following thawing, the 
samples were digested with pepsin as described above. To correct for loss of deuterium 
incurred under the experimental conditions, the peptide mass was determined using eq 1 
 
where D is the adjusted deuterium incorporation, m is the experimentally observed mass 
at a given time, m0% is the 0% or undeuterated control, m100% is the fully deuterated 
control, and N is the total number of exchangeable amide protons (and excludes the N-
terminal proton and any proline residues). To obtain the m0% value, 20 μg of protein was 
diluted 20-fold in the quench buffer followed rapidly by the addition of an equal amount 
of exchange buffer in D2O and digested with pepsin as described above. Thus, the final 
composition of deuterium in the quench and dilution solutions was identical for the 
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samples and the corresponding m0% control. To obtain the m100% value, a fully 
deuterated sample was prepared by incubating 20 μg of the protein overnight at room 
temperature in an 8 M guanidinium hydrochloride solution prepared in D2O. The protein 
sample was subsequently diluted 10-fold with 100 mM ammonium phosphate, pH 2.2 (at 
which concentration the denaturant does not interfere with proteolytic digestion), prior to 
pepsin treatment. On average, ~25% of the deuterium was lost due to back exchange. 
 
 
Figure 2. A. Sequence coverage of human cystathionine β-synthase obtained by MS 
analysis is shown in red. B. Limited proteolysis of human cystathionine β-synthase. 
Cystathionine β-synthase (5 nmol) was incubated at 37 °C with 750 units of porcine 
trypsin in 50 mM ammonium bicarbonate buffer, pH 8, in the absence (upper) or 
presence of 32 μM AdoMet (lower) for 0 s, 15 s, 30 s, 1 h, 2 h, and 4 h, respectively. The 
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reaction was quenched with 1 mM TLCK. The peptide mixture was resolved by 10% 
SDS PAGE and visualized by Coomassie blue staining. 
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Table 1. Cystathionine β-synthase peptides detected by mass spectrometry 
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HPLC-ESI Mass Spectrometry. LC/ESI-MS was employed to determine the extent of 
deuterium incorporation into individual peptides. The HPLC injection loop, 
chromatographic buffers, and all the tubing used in the LC-MS set up were submerged in 
ice to minimize deuterium loss in this step. The peptic peptides were separated by 
reversed phase HPLC using a microbore C18 column (5 cm length ×1 mm internal 
diameter, Micro-Tech Scientific, Cousteau Court, CA). The solvents used for separation 
were A (water, 0.3% formic acid) and B (acetonitrile, 0.3% formic acid). The gradient 
was 10-35% solvent B over 20 min at a flow rate of 40µl/min. Peptides were initially 
identified by tandem ESI-MS/MS sequencing. The masses of individual peptides in 
hydrogen exchange experiments were determined by ESI MS on a Quadrupole Time-of-
Flight mass spectrometer (Applied Biosystems). The peak for each peptide was integrated 
to obtain a centroid value using the Magtran computer program (17). The deuterium 
incorporation for each peptide was quantified by calculating the difference between the 
centroid values before and after deuterium exchange at a given time point using eq 1. 
Modeled Structures. A model for the regulatory domain of human cystathionine β-
synthase extending from residues 411-551 was calculated using SWISS-MODEL (18) 
using the 120 amino acid long CBS domain-containing protein from 
Methanothermobacter thermautotrophicus (Archae), strain delta H (PDB-ID 1PBJ). A 
docking model for the interaction between the known structure of the dimeric catalytic 
core (1M54) and the modeled structure of one regulatory domain was generated using 
ZDOCK, which combines pairwise shape complementarity with desolvation and 
electrostatics for scoring unbounded docking models (19). The search returned 3600 
docking positions, with scores ranging from 62.29 to 30.09. To generate a model of the 
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full-length dimer, the single regulatory domain obtained from the docked model was 
rotated around the noncrystallographic C2 symmetry axis of the A and B chains of the 
catalytic domain. To narrow down the number of docked candidates, the following filter 
was applied: that the CR of one of the exposed residues in the 356-370 peptide in the 
catalytic domain (358, 359, 362, 363, 365, 366 or 369) is within 4.5-6 Å of any CR in the 
regulatory domain. Of the top thirty hits on the score chart, only five satisfied this 
criterion and the remaining models were excluded. The five candidates fell into two 
groups with the top two and bottom three models being very similar with respect to their 
overall disposition of the catalytic and regulatory domains. The bottom three models 
placed the regulatory domains at two ends of the dimer, making it difficult to envision 
them as surfaces for tetramerization. Of the two top candidates (with the 2nd and 6th 
highest scores in the original list of 3600 hits), one (# 6) was selected for further analysis 
because it afforded more favorable interactions between the dimers at the presumed 
dimer-dimer interface. In this model, the distance between the last structured residue in 
the C-terminus of the catalytic domain (CR of K395) and the first structured residue in 
the N-terminus of the regulatory domain (CR of Q414) is 49.1 Å, a distance that can 
potentially be connected by the 20 intervening amino acids. 
 
 
2.4 Result and discussion 
Cystathionine β-synthase is poised at a critical metabolic junction where the decision 
to conserve homocysteine in the methionine cycle or to commit it to transsulfuration is 
made.  It is therefore not surprising that the enzyme is subjected to complex regulation, 
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which includes intrasteric inhibition imposed by the C-terminal domain and allosteric 
activation induced by AdoMet (4). Curiously, a subset of pathogenic cystathionine β-
synthase mutations have been described that map to the regulatory domain, display a 
higher level of basal activity, but are unresponsive to AdoMet (13, 14). This apparently 
paradoxical phenotype associated with pathogenic mutations is enigmatic and begs the 
question as to why they are correlated with disease. Structural insight into these 
regulatory modes is limited by the availability of the crystal structure of only the 
truncated, dimeric form of the enzyme lacking the regulatory domain. Hence, the relative 
juxtaposition of the regulatory and catalytic domains and the location of the dimer-dimer 
interface in the full-length enzyme are unknown. Kinetic studies indicate that the wild-
type enzyme equilibrates between at least two conformations, the “basal” state and the 
“activated state”, which is induced by AdoMet (Figure 1) (14). Limited proteolysis of 
wild-type cystathionine β-synthase in the presence and absence of AdoMet reveals 
differences in the kinetics of degradation of the protein (Figure 2), consistent with a 
conformational alteration. Thus, AdoMet stabilizes cleavage of the enzyme at the 
hypersensitive site between the catalytic and regulatory domains that converts the full-
length 63 kDa subunit to a truncated 45 kDa one. The pathogenic D444N mutant exhibits 
a kcat that is similar to the “activated” state of wild-type enzyme, albeit in the absence of 
AdoMet, while the truncated dimer exists in a “superactivated” state, with a kcat that is 
~4-fold higher than that of the “basal” state (Figure 1). The D444N mutation increases 
the Kd for AdoMet binding to the regulatory domain from 34 ± 2 μM to 510 ± 70 μM 
consistent with the observed insensitivity of the mutant to physiological concentrations of 
the allosteric effector (11). Hydrogen exchange MS was employed to assess whether 
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these discrete kinetic states could be correlated to conformational ones and to localize 
peptides that are sensitive to binding of AdoMet and to deletion of the regulatory domain. 
AdoMet-Induced Changes in Hydrogen Exchange Kinetics. The effect of AdoMet on the 
extent of deuterium incorporation was monitored over a 5 to 60 s time range. Analysis of 
the mass distribution profiles of > 50 peptides revealed a very focal conformational 
difference. The uncertainty in our mass measurements is ~ 0.2-0.3 deuteriums, and the 
difference in deuterium incorporation in all but one of the peptides from the two forms of 
the cystathionine β-synthase, fell within this range. Only a single peptide extending from 
residues 511-531 was identified that was sensitive to the presence of AdoMet (Figure 
3B). A significant shift in the average mass from 2503.36 (-AdoMet) to 2498.24 
(+AdoMet) was observed for this peptide indicative of either lower solvent accessibility 
or reduced hydrogen bonding in the presence of AdoMet. This represents a decrease in 
deuterium incorporation, from 85.5% to 51.6%, relative to the maximum deuterium 
incorporation possible for this peptide. The observed binomial distribution of isotope 
peaks for this peptide, which is characteristic of EX2 or “uncorrelated exchange” 
indicates that a high level of structural homogeneity exists during the deuterium 
exchange-in time (20). In other words, the unimodal distribution of the peptide mass 
envelope in the presence or absence of AdoMet indicates that under the present 
experimental conditions, the enzyme is seen to populate either the “basal” or the 
“activated” state and an equilibrium mixture between these two states is not detected. 
This is in contrast to the hematopoietic cell kinase SH3 domain in which interconverting 
conformers are detected by hydrogen exchange MS (21). Two limitations of the hydrogen 
exchange MS approach  that are also pertinent to this study bear note. First, differences in 
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deuterium exchange kinetics of peptides that occur on a fast time scale (<5 s) would have 
been missed in this study. Second, although the 76% coverage of amino acids obtained in 
this experiment is relatively high, differences in the remaining 24% of the protein are 
missed. Approximately half of the missing residues that we were unable to detect reside 
in a protease resistant region of the protein, as discussed under Methods, with most of the 
remainder being in the N-terminal heme domain.  
The D444N Mutant is Conformationally Locked in the “Activated” State. Since the 
pathogenic D444N mutant is unresponsive to physiological concentrations of AdoMet 
(14), the mutation could in principle have locked the protein in either the “basal” or the 
“activated” conformation. To distinguish between these two possibilities, the kinetics of 
hydrogen exchange for the D444N mutant were compared to that of wild type enzyme. 
They were found to be virtually identical to that of wild-type enzyme in the presence of 
AdoMet (Figure 3B). Thus, the D444N is locked in the “activated” conformation in the 
absence of AdoMet binding, which is consistent with its high basal activity and its 
insensitivity to physiological concentrations of AdoMet (Figure 3). 
Modeled Structure of the C-Terminal Regulatory Domain. Conformational perturbation 
of the 511-531 peptide is particularly interesting since it is located in the C-terminal 
module of the enzyme (Figure 1) where AdoMet is predicted to bind (11). This module 
harbors a tandem repeat of two CBS domains, a secondary structure motif that is 
predicted to adopt a β-α-β-β-α fold and is found in diverse proteins in all three kingdoms 
of life (22). This domain, which derives its name from its presence in cystathionine β-
synthase, is believed to function as an energy-sensing module and typically binds 
nucleotides (11). Since the structure of the full-length cystathionine β-synthase is 
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unavailable, we have generated a homology modeled structure of the C-terminal 
regulatory domain (Figure 3C) using the coordinates for a CBS domain protein from M. 
thermoautotrophicus. Pairs of CBS domains are known to dimerize to form a stable 
globular domain, which is also the case in the modeled structure for the cystathionine β-
synthase C-terminal domain. The 511-531 peptide resides in the CBS2 domain and 
exhibits sensitivity to AdoMet binding and also to the D444N mutation in the CBS1 
domain. The sensitivity of the 511-531 peptide could be a consequence of its proximity to 
the binding site for AdoMet and/or its location on the pathway of allosteric signal 
transduction, a distinction that cannot be made by the hydrogen exchange MS approach. 
 
Figure 3. Mapping allosteric effects. A. Comparison of the mass analysis of the 511-531 
peptide after 30 s of hydrogen exchange in wild-type enzyme without (upper) and with 
(middle) AdoMet and in the D444N mutant lacking AdoMet (lower). B. Location of the 
513-531 peptide (in navy) in the modeled structure of the C-terminal domain. The CBS1 
and CBS2 domains are shown in red and blue, respectively, and the model extends from 
residues 413-544 of cystathionine β-synthase. 
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Identification of Peptides That Respond to Deletion of the Regulatory Domain. C-
Terminal truncation leads to a change in the oligomerization state from R4 to R2 and 
generates a “superactivated” form of the enzyme (Figure 1). This form is observed 
physiologically in response to a proinflamatory challenge induced by TNFR or 
lipopolysaccharide and increases the flux of homocysteine through cystathionine β-
synthase, leading eventually to increased synthesis of the antioxidant, glutathione (10). 
Surprisingly, deletion of the regulatory domain leads to very focal changes in the kinetics 
of deuterium exchange within the time frame of our observations, which extended from 5 s 
to 21 h. Only two peptides, contiguous in sequence space, displayed significant 
differences in deuterium incorporation (Figure 4A-D). The first peptide extends from 
residues 356-370 (Figure 4E). Several amino acids in this segment are quite surface-
exposed, particularly residues 358, 359, 362, 363, 365, 366, and 369. It is interesting to 
note that several pathogenic mutations have been reported in this stretch of cystathionine 
β-synthase including one, R369C/ H, which is surface exposed in the dimeric structure 
(12). A maximum difference in deuterium incorporation in this peptide was seen after a 1 
min exposure to D2O (Figure 4B). The centroid mass shifted from 1635.234 (full-length) 
to 636.528 in the truncated enzyme, which represents a change from 25% to 41% of 
maximal deuterium incorporation seen for this peptide. The second peptide, extending 
from residues 371-385, is largely buried and resides at the interface between the 
monomers (Figure 4F). Only residues 382-384 in this peptide are surface-exposed and are 
located at the base of a cavern. A maximum mass difference in this peptide is observed 
after 10 min of exposure to D2O (Figure 4D). The centroid mass shifted from an average 
of 1788.969 (full-length) to 1791.342 (truncated), which represents an increase from 25% 
42 
to 52.1% of the maximal deuterium incorporation seen for this peptide. Several patient 
mutations have been identified in this stretch of cystathionine β-synthase, including one, 
K384N/E that is exposed in the dimeric structure (12). 
 
Figure 4. Mapping intrasteric effects. A. Comparison of the kinetics of hydrogen 
exchange of peptides 356-370 (A) and 371-385 (B) that respond to deletion of the 
regulatory domain. The spectra in A and B represent samples that were quenched after 1 
min. C and D show the differences in the kinetics of deuterium incorporation in the 356-
370 peptide in the truncated (circles) and full-length (triangles) protein (C) and for the 
371-385 peptide in truncated (circles) and full length (triangles) protein (D). The closed 
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and open symbols represent data from two independent experiments. E. Location of the 
356-370 and 371-385 peptides (in navy) in the crystal structure of the catalytic core 
shown in surface representation. The subunits are shown in gray and blue, and the 
residues, P78 and K102, that are mutated in some homocystinuric patients and lead to 
lack of AdoMet sensitivity are shown in yellow. F. A different view of the truncated 
dimer highlighting the location of the 371-385 peptide. 
 
 
 
A Modeled Structure for Full-Length Cystathionine β-Synthase. The hydrogen exchange 
data identifies two surfaces in the dimeric structure that experience greater solvent 
accessibility or reduced hydrogen bonding interactions upon deletion of the regulatory 
domain (Figure 4E and 4F). We have employed the MS data in conjunction with the 
reported properties of cystathionine β-synthase to guide our selection of a model for the 
full-length enzyme (Figure 5) generated by the ZDOCK program. It is important, 
however, to first note some limitations of this model-building exercise. In principle, it is 
possible that the peptides identified in this study report indirectly on the loss of the 
regulatory domain with a consequent change in the oligomeric organization, and that the 
actual interaction surfaces were missed due to the time course of the kinetic analysis. 
Hydrogen exchange rates for individual amides in a protein can vary over several orders 
of magnitude (23), and only those amides with half-lives for exchange that are similar to 
the experimental labeling time report on structural changes (20). Thus, a limitation of this 
study is that hydrogen exchange kinetics were monitored in a time range from seconds to 
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hours, and differences in dynamics and/or structure that resulted in differences in 
deuterium incorporation rates on a shorter time scale would have been missed. We 
propose that both the 356-370 and the 371-385 peptides are likely to be reporting on 
deletion of the regulatory domain based on the following lines of reasoning. 
Cystathionine β-synthase exists as a homotetramer that separates into dimers following a 
proteolytic clip between the catalytic and regulatory domains (16). Thus, interactions 
between the regulatory domains appear to be more important in preserving the tetrameric 
structure than interactions between the catalytic domains. We propose that the 356- 370 
peptide is involved in making direct contact with the regulatory domain based on its 
proximity to the P78 and K102 residues (Figure 4E). Mutations in these two residues 
(P78R/K102N) are inherited as linked pathogenic mutations in homocystinurics (12). The 
P78R/K102N mutations impair sensitivity to AdoMet, suggesting their proximity to the 
regulatory domain (Sen and Banerjee, manuscript in preparation). The docked model 
generated by ZDOCK provides an excellent fit to our assignment of this region as the 
regulatory-catalytic domain interface (Figure 5 A). The exposed surface of the 371-385 
peptide is located at the bottom of a cavity (Figure 5A) and leads to a short helix that 
ends in a loop representing the C-terminus of the catalytic domain. In the intact structure, 
this loop would lead to the regulatory domain and its truncation could perturb the 
environment of the 371-385 peptide, resulting in changes in the kinetics of deuterium 
incorporation. The location and the limited surface exposure of this largely buried peptide 
appear to be incompatible with its possible involvement in the dimer-dimer interface 
(Figure 5). Based on the docked model of the dimer, we propose a schematic model for 
the organization of the full-length enzyme (Figure 5B). In this model, the regulatory 
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domains on adjacent monomers are on opposite edges of the dimer and contact the mirror 
domains in the tetramer. This model is consistent with the known properties of the wild 
type and mutant enzymes, the role of the regulatory domain in tetramerization, and with 
the separation of dimers following deletion of this domain. In this model, the regulatory 
domains form the dimer-dimer interface and generation of the truncated dimer exposes on 
the catalytic domain only those surfaces that are sensitive to loss of the regulatory 
domain. This is consistent with our ascription of the sensitivity of both the 356-370 and 
371-385 peptides to deletion of the regulatory domain. The validity of this model will of 
course be tested as additional insights into cystathionine β-synthase are gained and 
ultimately by the crystal structure of the full-length enzyme itself. 
 
Figure 5. Modeled structure of full-length cystathionine β-synthase. A. A docked model 
showing the predicted juxtaposition of the regulatory domains and the catalytic core of 
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the dimer. The two catalytic domains are shown in light gray and light blue, respectively, 
while the corresponding regulatory domains are shown in darker shades. The light blue 
subunit is behind the plane of the light gray subunit and not visible. A portion of the 356-
370 peptide (in navy) on one of the chains and of the heme (in red) are visible in this 
view. This model was generated using ZDOCK as described under Methods. B. Model of 
the full-length cystathionine β-synthase showing the relative juxtaposition of two R2 
dimers. The color scheme used in A is retained. 
 
 
 
2.5 Conclusions 
In summary, we have localized focal conformational changes in wild-type 
cystathionine β-synthase that are induced by AdoMet, to a peptide which spans residues 
511- 531 in the regulatory domain. Furthermore, we have demonstrated that this 
“activated” conformation is mimicked by the pathogenic D444N mutation, explaining its 
known insensitivity to AdoMet (14, 24). This approach could be useful for providing 
structural insights into other pathogenic mutants. The kinetics of hydrogen exchange 
reveal two surfaces that are sensitive to deletion of the regulatory domain. This 
information has been used to build a structural model of the full-length human enzyme 
(Figure 5), which could be helpful in providing a framework for understanding the 
interactions between the regulatory and catalytic modules and the penalties associated 
with pathogenic mutants.  
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Chapter 3 
A pathogenic Linked Mutation in the Catalytic Core of Human 
Cystathionine β-Synthase Disrupts Allosteric Regulation and Allows Kinetic 
Characterization of a Full-Length Dimer 
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3.1 Abstract 
Cystathionine β-synthase catalyzes the condensation of serine and homocysteine to 
yield cystathionine and is the single most common locus of mutations associated with 
homocystinuria. In this study, we have examined the kinetic consequences of a pair of 
linked patient mutations, P78R/K102N, that are housed in the catalytic core of the protein 
and compared it to the effects of the corresponding single mutations. The P78R mutation 
affords purification of a mixture of higher order oligomers, P78R-I, which resembles the 
mixed quaternary state associated with wild type enzyme. However, unlike wild type 
enzyme, P78R-I converts over time to P78R-II, which exists predominantly, as a full-
length dimer. The specific activities of the K102N, P78R-I and P78R-II mutants in the 
absence of AdoMet are ~3-, 9- and 3-fold lower than of wild-type enzyme and are 
stimulated 2.9-, 2.5- and 1.4-fold respectively by AdoMet. However, when linked, the 
specific activity of the resulting double mutant is comparable to that of wild-type enzyme 
but it is unresponsive to AdoMet, revealing that interactions between the two sites 
modulate the phenotype of the enzyme. Steady-state kinetic analysis for the double 
mutant reveals a sigmoidal dependence on homocysteine that is not observed with wild-
type enzyme, which is ascribed to the mutation at the K102 locus and indicates changes 
in subunit interactions. Hydrogen-deuterium mass spectrometric analyses reveals that 
even in the absence of AdoMet, the double mutant is locked in an activated conformation 
that is observed for wild-type enzyme in the presence of AdoMet, providing a structural 
rationale for loss of this allosteric regulation. To our knowledge, this is the first example 
of mutations in the catalytic core of cystathionine b-synthase that result in failure of 
AdoMet-dependent regulation. Furthermore, analysis of individual single mutations has 
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permitted for the first time, partial kinetic characterization of a full-length dimeric form 
of human cystathionine β-synthase.  
 
 
3.2 Introduction 
Cystathionine β-synthase is a pyridoxal phosphate (PLP)1-dependent protein that 
catalyzes the condensation of serine and homocysteine to give cystathionine and is 
activated by the allosteric effector, AdoMet (1-3). It catalyzes the first step in the 
transsulfuration pathway connecting the methionine cycle to cysteine production. 
Mutations in cystathionine β-synthase are the single most common cause of hereditary 
hyperhomocysteinemia and over one hundred pathogenic mutations have been described 
so far (4). They represent a roadmap of residues that are important for the structural 
and/or functional integrity of the enzyme and characterization of these mutants have 
begun to provide invaluable insights into the organization and regulation of this unusual 
enzyme (5-9). The pathogenic mutations are dispersed over all three domains of the 
modular protein: the N-terminal heme domain, which is found in some but not all 
eukaryotic cystathionine β-synthases, the central active site domain where PLP is bound 
and the C-terminal regulatory domain, which is required for allosteric activation of the 
enzyme by AdoMet.  
The purified human enzyme is a homooligomer with a subunit mass of 63 kDa and 
exists in multiple higher order oligomeric states ranging from a dimer to a 16-mer (10), 
which have not been purified and characterized separately to date (Figure 1). A 
hypersensitive site leads to the facile proteolytic separation between the catalytic core and 
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the regulatory domain (11). The resulting truncated enzyme is a well-behaved dimer that 
is not prone to aggregation unlike the full-length enzyme. It has a subunit mass of 45 kDa 
and exhibits an ~4-fold higher kcat than the full-length form (9) but is unresponsive to 
AdoMet (12). The regulatory domain thus appears to be autoinhibitory and its cleavage 
alleviates inhibition of cystathionine β-synthase activity (11-13). Furthermore, truncation 
is accompanied by a change in the oligomerization state of the protein from tetramer to 
dimer. These results reveal a complex role for the C-terminal domain in mediating 
regulation of cystathionine β-synthase including intrasteric and allosteric regulation and 
in the oligomerization of the protein beyond the dimeric state. 
 
Figure 1. Model of the oligomeric heterogeneity seen with human cystathionine β-
synthase. It is not known whether the equilibrium between the different oligomeric states 
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involves dissociation into monomers and has been shown for simplicity, to involve either 
the dimer or the tetramer. The P78R mutation shifts the equilibrium towards the full-
length dimer compared to wild type enzyme. Deletion of the regulatory domain leads to a 
truncated dimer. 
 
 
A class of pathogenic mutations housed in the regulatory domain has been described 
that display a common and seemingly paradoxical phenotype (6, 9, 14, 15). When 
mimicked in vitro, these regulatory domain mutants are unresponsive to activation by 
AdoMet but exhibit robust enzyme activity comparable to or greater than that of wild 
type enzyme (6, 9). Mathematical modeling of methionine metabolism provides a 
rationale for the build up of homocysteine by the mere loss of allosteric activation of 
cystathionine β-synthase, particularly under conditions of methionine excess, confirming 
an important role for AdoMet-dependent regulation in intracellular homocysteine 
homeostasis (16).  
The crystal structure of the catalytic core of cystathionine β-synthase has been 
reported and reveals the relative juxtaposition of the heme- and PLP-domains (17, 18). 
However, the structure of the regulatory domain and its interaction with the catalytic core 
are unknown. The C-terminal domain is comprised of a tandem repeat of two CBS 
domains, a β-α-β-β-α secondary structure motif that is found in diverse proteins in all 
three kingdoms of life and believed to function as an energy sensor (19, 20). A 
homology-modeled structure of the catalytic core has been generated based on the crystal 
structure of a CBS-domain containing protein from Methanobacter thermoautotrophicus 
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(21). The only structural insights that are presently available on the mechanism of 
allosteric signal transduction between the regulatory and the catalytic domain derives 
from hydrogen exchange MS studies, which identified a single peptide in the CBS2 
domain extending from residues 511-531 that exhibits a lower propensity for deuterium 
incorporation in the presence of AdoMet (21). In combination with other hydrogen 
exchange MS data, these studies have been used to build a docked model of the 
regulatory and catalytic domains (Figure 2) (21), which in the absence of a crystal 
structure for the full-length enzyme, provides a useful framework for interpreting the 
functional data (22). Although the regulatory domain is believed to house the binding site 
for AdoMet (20), the role of the CBS domains in cystathionine β-synthase, the protein 
from which this motif derives its name, is unknown.  
In this study, we report on the characterization of a linked patient nucleotide 
mutation, C233G/G306C, corresponding to P78R/K102N in the polypeptide, which are 
located in the catalytic core of the protein (Figure 2). These paternally inherited cis 
mutations have been described in three siblings who, like most homocystinurics, are 
compound heterozygotes, and have a maternally inherited E239K mutation in the other 
allele (23). Interestingly, the siblings display a wide range of clinical phenotypes from 
severe (in the two sisters) to benign (in the brother) despite sharing an identical genotype 
at this locus, which indicates possible gender-dependent modulation of the expression of 
cystathionine β-synthase-dependent homocystinuria. Previous studies of the 
P78R/K102N mutation were limited to cell lysates of Escherichia coli expressing 
recombinant cystathionine β-synthase (23). We have analyzed, using purified 
recombinant human cystathionine β-synthase, the biochemical penalties associated with 
57 
the individual mutations to elucidate the contribution of each locus to the phenotype of 
the double mutant. The P78R mutation allowed for the first time, limited kinetic 
characterization of a full-length dimeric form of cystathionine β-synthase. Interestingly, 
interactions between the K102N and P78R mutations result in a compound phenotype 
that is similar to but also distinct from those of the single mutants. The double mutant is 
as active as the wild-type enzyme but is unresponsive to the allosteric activator, AdoMet. 
The loss of allosteric regulation is explained by hydrogen exchange MS data, which 
revealed that the linked mutation locks the protein in a conformation achieved by wild-
type enzyme in the presence of AdoMet. To our knowledge, this is the first example of 
mutations in the catalytic core that confer AdoMet insensitivity, exhibit high basal 
activity and thus resemble a subset of regulatory domain mutations that have been 
described in homocystinuric patients. 
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Figure 2. Modeled structure of full-length cystathionine β-synthase dimer showing 
locations of the P78 and K102 residues. The structure was generated by docking the 
crystal structure of the catalytic core of cystathionine β-synthase (in tan) with the 
homology modeled structure of the regulatory domain (in scarlet) as described previously 
(21). The locations of P78 and K102 (in blue ball and stick representation) are indicated 
as are of the heme (in red) and PLP (in blue). 
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3.3 Material and methods 
Materials-Serine, IPTG, and   D, L-homocysteine were purchased from Sigma. [14C]-
Serine (158 mCi/mmol) was purchased from Amersham. GST Sepharose and SuperdexTM 
200 were purchased from Pharmacia. Deuterium oxide (100.00 atom % D) was purchased 
from Sigma. AdoMet 1,4-butanedisulfonate was a generous gift from Knoll Farmaceutici 
Spa (Milano, Italy). Thrombin was purchased from GenTrac Inc. Middleton, WI. 
Complete tablets (protease cocktail inhibitors) were purchased from Roche Diagnostics 
(Mannheim, Germany). 
Generation of the CBS Mutants and Protein Purification-The single mutants K102N, 
P78R and the double mutant P78R/K102N, were generated by site-directed mutagenesis 
using the Quick Change Kit from Stratagene. The template for mutagenesis was 
pGEX4T1/hCBS containing wild-type human cystathionine β-synthase gene fused in-
frame with glutathione S-transferase (24). The forward and the reverse primers that were 
employed were:  
P78R: Sense: 5' :CCAAAATCTTGCGAGATATTCT  
 Antisense: 5': AGAATATCTCGCAAGATTTTTGG 
K102N: Sense: 5': AAGTTCGGCCTGAACTGTGAGCTCTTGGC  
 Antisense: 5': GCCAAGAGCTCACAGTTCAGGCCGAACTT 
The double mutant, P78R/K102N, was constructed by introducing the P78R mutation 
using the single mutant, K102N as template, and the appropriate set of primers. The 
mutations were confirmed by nucleotide sequencing at the Genomics Core Facility at the 
University of Nebraska Lincoln.  
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Protein purification and enzyme assays- The mutant enzymes were expressed in E. coli 
and purified as glutathione S-transferase fusion proteins using recombinant expression 
systems essentially as described for wild-type enzyme (24). The cell extract was prepared 
and sonicated in 50 mM Tris HCl pH 8, supplemented with protease inhibitor cocktail 
tablets (Roche Diagnostics). One tablet was used for the 300 ml cell extract prepared 
from a 6 l culture. 
Following partial proteolysis by thrombin (1 U/mg protein) to remove the GST tag, 
the K102N and P78R/K102N mutants were dialyzed to remove glutathione and purified 
by anion exchange chromatography as described previously (24). The P78R mutant was 
purified following thrombin digestion by gel filtration chromatography using a 90 X 3 cm 
Superdex TM 200 column eluted isocratically with 50 mM Tris HCl containing 0.1 M 
NaCl.  Over 50 mg of ~90% pure protein was obtained from 6 l of culture for each 
mutant.  
The enzyme activity was assayed under aerobic conditions using 30 mM [14C]-serine 
and 30 mM D,L-homocysteine as described previously (13). One unit of enzyme activity 
catalyzes the conversion of 1 µmol cystathionine min-1 at 37˚C. Protein concentration 
was determined by the Bradford method using bovine serum albumin as a standard. The 
concentration of the stock homocysteine solution was determined immediately prior to 
the experiments by titration with 5,5'-dithiobis 2-nitrobenzoic acid and estimated using a 
value of ε412 of 13,600 M-1 cm -1. 
Steady-state kinetic analysis was performed in the standard radiolabeled assay and 
initiated by addition of homocysteine. The reaction mixture was incubated for 30 min at 
37˚C and terminated by the addition of 200 μl of 10% trifluoroacetic acid. The 
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radiolabeled product, [14C]-labeled cystathionine, was separated from [14C]-labeled serine 
as described previously (13). The kinetic sbehavior of some mutants (indicated in Table 
I) showed a sigmoidal rather than a hyperbolic dependence on substrate concentration 
and these data were fitted to the Hill equation to obtain the Hill coefficient.  
Hydrogen-deuterium exchange mass spectrometry- These experiments were performed 
with wild type and the P78R/K102N forms of cystathionine β-synthase exactly as 
described previously (21). To correct for loss of deuterium incurred under the 
experimental conditions, the peptide mass was determined using equation 1 where D is 
the adjusted deuterium incorporation, m is the experimentally observed mass at a given 
time, m0% is the 0 percent or undeuterated  
 D = m − m0%( )
(m100%−m 0%)
XN  Equation 1 
control, m100% is the fully deuterated control and N is the total number of exchangeable 
amide protons (and excludes the N-terminal proton and any proline residues). To obtain 
the m0% value, 20 µg of protein was diluted 20-fold in the quench buffer followed rapidly 
by the addition of an equal amount of exchange buffer in D2O and digested with pepsin 
as described above. Thus, the final composition of deuterium in the quench and dilution 
solutions was identical for the samples and the corresponding m0% control.  
To obtain the m100% value, a fully deuterated sample was prepared by incubating 20 
µg of the protein overnight at room temperature in an 8 M guanidinium hydrochloride 
solution prepared in D2O. The protein sample was subsequently diluted 10-fold with 100 
mM ammonium phosphate, pH 2.2 (at which concentration the denaturant does not 
interfere with proteolytic digestion), prior to pepsin treatment.  
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HPLC-ESI Mass Spectrometry- LC/ESI-MS was employed to determine the extent of 
deuterium incorporation into individual peptides as described previously (21). The 
masses of individual peptides in hydrogen exchange experiments were determined by 
ESI-MS on a Quadrupole time-of-flight mass spectrometer (Applied Biosystems). The 
peak for each peptide was integrated to obtain a centroid value using the Magtran 
computer program (25). The deuterium incorporation for each peptide was quantified by 
calculating the difference between the centroid values before and after deuterium 
exchange at a given time point using equation 1.  
Native gel electrophoresis for determining oligomeric state- Protein samples (30 µg each) 
were separated on a 4-20% gradient gel under nondenaturing conditions. The gels were 
run at 4˚C at 120 V and 15 mA current. 
 
 
3.4 Results 
Purification and Oligomeric States of the K102N, P78R and P78R/K102N Mutants- The 
recombinant single and double mutants were obtained in at least 90% purity as 
determined by electrophoresis under denaturing conditions and by the ratio of the 280 nm 
to 428 nm absorption peak (which is ~1 for pure wild type enzyme (24)). The PLP 
content of both the single and the double mutants was identical to that of wild type 
enzyme, i.e. one PLP per subunit (data not shown). The P78R single mutant exhibited a 
shift in the equilibrium distribution of oligomeric states that was detected by analysis of 
freshly purified enzyme. Gel filtration chromatography resulted in elution of P78R as a 
broad peak and partial resolution of two species designated hereafter as P78R-I and 
63 
P78R-II respectively, as revealed by native gel electrophoresis (Figure 3). P78R-I 
migrated as a mixture of higher-order oligomers, which is also observed with wild-type 
enzyme, whereas P78R-II is predominantly in the dimeric state. Storage of P78R-I at 4˚C 
for 24-48 h resulted in its conversion to the P78R-II state. In contrast, the K102N and the 
double mutant behaved like wild-type enzyme by native gel chromatography and exists 
as a mixture of higher-order quaternary states. 
 
Figure 3. The P78R-II mutant behaves like a dimer. Native gel electrophoresis of wild 
type cystathionine β-synthase and various single and double mutants shows heterogenous 
oligomeric states. P78R-I* refers to the form obtained by overnight incubation of P78R-I 
at 4˚C. Lane 1 shows migration of molecular weight markers and lane 8, the truncated 
dimeric form of cystathionine β-synthase (T-α2) which has a molecular mass of ~90 kDa.  
 
 
 
Kinetic Properties of the K102N, P78R and P78R/K102N Mutants- The steady-state 
kinetic parameters for the variants were compared with those of wild type enzyme (Table 
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1). Each of the single mutants diminished the specific activity with the K102N showing a 
3-fold lower activity (65 μmol mg-1 h-1) and the P78R-I and P78R-II forms exhibiting 9- 
(19 μmol mg-1 h-1) and 3-fold (62 μmol mg-1 h-1) lower activity than wild type enzyme 
(178 μmol mg-1 h-1). Overnight storage of P78R-I at 4˚C resulted in its conversion to 
P78R-II and was accompanied by a 3-fold increase in specific activity to 58 ± 5 μmol 
mg-1 h-1. Interestingly, the deficits in activity associated with each of the single mutations 
were negated in the double mutant (169 μmol mg-1 h-1), which was as active as wild-type 
enzyme in the absence of AdoMet. 
Some changes were observed in the kinetic parameters for the substrates. The KM for 
serine is ~2-fold higher for the K102N and P78R/K102N mutants and ~4-fold higher for 
the P78R-II mutant compared to wild-type enzyme. A sigmoidal dependence of activity 
on serine concentration was seen with P78R-I with a Hill coefficient of 2.4. Sigmoidal 
kinetics are observed with the K102N single and the P78R/K102N double mutants when 
homocysteine is the variable substrate with a Hill coefficient of 3, indicating positive 
cooperativity. The KM for L-homocysteine is 2-fold higher for the K102N mutant, lower 
for the P78R-II mutant, and comparable to wild-type enzyme for the double mutant 
(Table I).  
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Table 1. Comparison of kinetic parameters of the single and double mutants with wild-
type cystathionine β-synthase 
 
Enzyme Wild type P78R-I P78R-II K102N K102N/P78R
S.A.a(+AdoMet) 378 ± 17 47 ± 4 84 ± 2 185 ± 4 169 ± 9 
kcatb (+AdoMet) 6.6 sec-1  0.8sec-1  1.4 sec-1  3.0 sec-1  3.0 sec-1 
S.A. (-AdoMet) 178 ± 5 19 ± 2 62 ± 0.5 65 ± 9 169 ± 9 
kcat (-AdoMet) 3.0 sec-1  0.3 sec-1  1.0 sec-1  1.0 sec-1  3.0 sec-1  
KMSer (mM)  
Hill Coefficientc 
2.0 ± 0.3 
- 
1.9 ± 0.2 
2.4 ± 0.7 
8 ± 3 
- 
3.8 ± 0.8 
- 
5.1 ± 0.8 
- 
KMHcy (mM) 
Hill Coefficient 
5.0 ± 0.9 
- 
5 ± 2 
- 
2.4 ± 0.5 
- 
10 ±1 
3 ±1 
4.4 ± 0.3 
3.0 ± 0.2 
 
a Specific activity is in units of µmol cystathionine formed h-1 mg-1 protein.  
b kcat is calculated based on the molecular mass of the monomer. Hill coefficients 
are reported only when a sigmoidal dependence on substrate concentration was 
observed. In all other instances, the KM values were obtained by Michaelis-
Menten analysis of the data set.  
 
 
 
The P78R/K102N Mutant is Insensitive to Allosteric Regulation. In the presence of 
AdoMet, the specific activity of wild-type cystathionine β-synthase increases ~2-fold 
from 178 μmol mg-1 h-1 to 378 μmol mg-1 h-1 (24). The K102N and P78R-I variants 
exhibit sensitivity to AdoMet and were activated 2.9- and 2.5-fold respectively. In 
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contrast, P78R-II, which exists predominantly in the dimeric state, shows diminished 
activation (1.4-fold) by AdoMet. Based on the densitometric analysis of the native gel, 
we estimate that ~30% of P78R-II is present in the higher oligomeric state. Thus, the 
AdoMet responsiveness of P78R-II indicates that the full-length dimer is also sensitive to 
allosteric regulation. In contrast, the P78R/K102N double mutant is unresponsive to 
AdoMet. Thus, interaction between the P78 and K102 positions in the double mutant 
results in loss of allosteric regulation. 
Hydrogen Exchange MS Reveals Conformational Lock in the P78R/K102N Mutant. 
Hydrogen exchange MS was employed to determine if the insensitivity of the double 
mutant results from a conformational lock in the kinetically distinguishable “basal” and 
“activated” states (Figure 4A). Of the ~50 peptides that were identified for the double 
mutant, a significant difference in the extent of deuterium incorporation was observed in 
only one peptide, extending from residues 511-531 (Figure 4B) with a mass of 2502.704. 
The same peptide in wild-type enzyme had previously been shown to exhibit a downshift 
in the centroid mass from 2503.36 in the absence to 2498.24 in the presence of AdoMet 
(21). This corresponds to a decrease in maximal deuterium incorporation from 85% in the 
wild-type enzyme to 51% in the double mutant. The P78R/K102N double mutant thus 
appears to be conformationally locked in the “activated” state, explaining its insensitivity 
to AdoMet. The decrease in deuterium concentration upon exposure to AdoMet in wild-
type enzyme and in the double mutant as isolated, indicates decreased solvent exposure 
and/or hydrogen bonding interaction in this conformation. 
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Figure 4. Conformational change induced by AdoMet binding to cystathionine β-
synthase. A. Model of an AdoMet-induced conformational change in cystathionine β-
synthase. The model correlates differences in kinetic properties associated with the basal 
and activated states of cystathionine β-synthase with the structural changes revealed by 
hydrogen-deuterium mass spectrometry. The P78R/K102 patient mutation is locked in 
the activated conformation even in the absence of AdoMet.  B. Mass spectrometric 
analysis of wild-type and the P78R/K102N mutants of cystathionine β-synthase. 
Hydrogen-deuterium exchange mass spectrometric analysis of cystathionine β-synthase 
identified a single peptide extending from residues 511 to 531 that revealed a difference 
in the centroid mass after 30 s of hydrogen exchange in the presence (m/z = 624.803) 
versus absence (m/z = 625.676) of AdoMet. The same peptide in the double mutant in the 
absence of AdoMet, exhibited a centroid mass corresponding to that observed with wild-
type enzyme in the presence of AdoMet. 
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Discussion 
Pathogenic mutations represent Nature’s map of residues that are important for the 
structural and/or functional integrity of proteins. In the case of cystathionine β-synthase, 
over 100 patient mutations have been described that are dispersed across all three 
domains of the modular protein (4). Biochemical characterizations of a limited number of 
missense mutations that are remote from the active site have been described (5-9) and 
have provided novel insights into clinically important phenotypes associated with specific 
mutations, viz. pyridoxine responsiveness. A subset of pathogenic mutations, clustered in 
the CBS1 domain of the regulatory module are associated with an interesting phenotype, 
i.e. they show robust basal activity but are unresponsive to allosteric activation by 
AdoMet (6, 9, 14). Biophysical characterization of one such mutant, D444N, revealed 
that it is conformationally locked in an activated state that is observed with wild-type 
enzyme only in the presence of AdoMet (21). These studies reveal that AdoMet binding 
to the regulatory domain shifts the conformation of cystathionine β-synthase from a 
kinetically distinguishable “basal” state to an “activated” state, which in turn, increases 
the activity of the enzyme. In this study, we have examined the penalties associated with 
a pair of linked mutations P78R/K102N, described in homocystinuric patients and 
compared them to the deficits associated with the single mutations.  
Wild-type human cystathionine β-synthase exists as a mixture of oligomeric states 
with higher-order oligomers being the predominant species. Analysis of wild-type 
cystathionine β-synthase by blue native gel electrophoresis reveals the presence of 
oligomers ranging from a dimer to ~16-mers (10). However, the kinetic properties 
associated with the full-length dimer have not been reported because of the difficulty in 
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separating the various oligomeric states in pure form. P78 is located at the periphery of 
the dimer interface in the crystal structure of truncated cystathionine β-synthase (22, 26) 
(Figure 2). Unlike wild-type enzyme, chromatography of P78R results in partial 
separation of two oligomeric states monitored by native gel chromatography, which 
correspond to a predominantly full-length dimeric form (P78R-II) and a mixture of higher 
oligomeric forms (P78R-I). The P78R-I form is unstable and is converted to the P78R-II 
state over 24 h at 4˚C, permitting limited kinetic characterization of the full-length 
dimeric form of cystathionine β-synthase (Table 1). The principal findings for P78R-II, 
which is enriched in the full-length dimer, is that it is active, albeit ~3-fold less so than 
wild-type enzyme, and is responsive to allosteric activation by AdoMet. The KM values 
for both serine and homocysteine for P78R-II are similar to those for wild-type enzyme. 
The P78R-I form, which is a heterogeneous mixture of oligomeric states is 3-fold less 
active than P78R-II and exhibits KM values for the two substrates that are similar to wild-
type enzyme. Extrapolating from these results to wild-type enzyme, suggests that a 
dimeric form of cystathionine β-synthase would be active and AdoMet responsive. The 
physiological relevance of the oligomeric heterogeneity associated with purified human 
cystathionine β-synthase is not known, nor what ligands or metabolic state might favor 
one versus other structures. Since the full-length dimer of P78R is associated with higher 
activity compared to the mixed higher-order oligomeric state, P78R-I, it raises the 
possibility that stabilization of the full-length dimer may be used as a mechanism for 
upregulation of wild-type cystathionine β-synthase under certain conditions.  
The instability of the P78R-I form together with the absence of the homogenous 
dimeric form in the P78R-II pool, limited our ability to further characterize their 
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oligomeric states by biophysical methods viz. analytical ultracentrifugation, which 
yielded variable results. It also raises questions about whether the kinetic properties of the 
P78R-II species that we have determined, truly reflect those for the full-length dimer. In 
fact, we estimate that ~30% of the P78R-II pool represents higher-order oligomers. 
Unfortunately, we have been unable to purify the dimeric form any further using various 
chromatographic columns. Nonetheless, the observed differences in the kinetic properties 
between P78R-I and -II, particularly with respect to specific activity, lends confidence at 
least to the qualitative differences between the dimer and the mixed higher oligomeric 
states that are reported in this study.  
The principal in vitro biochemical phenotypes associated with the linked patient 
mutation, P78R/K102N, are high basal activity comparable to wild-type enzyme and 
AdoMet unresponsiveness. The high basal activity exhibited by the P78R/K102N enzyme 
indicates that the mutant retains a full complement of PLP. This is curious in light of the 
B6-responsive phenotype associated with patients carrying this mutation (23). It is 
possible that the B6-responsiveness is associated with the second mutation in these 
patients, E239K. We also note the seeming paradox between pyridoxine responsiveness 
in patients carrying the I278T mutation in cystathionine β-synthase, which is not 
reflected in an altered affinity for PLP in the expressed protein (27). This observation led 
the authors of the study to suggest that the clinical response to pyridoxine may involve 
multiple mechanisms (27).   
Since neither single mutant exhibits this property, we conclude that their interaction 
in the double mutant is responsible for this phenotype. The insensitivity of the double 
mutant to AdoMet could arise in principle from its inability to bind the allosteric activator 
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and therefore be locked in the “basal” conformation or to it being locked in the 
“activated” conformation that is seen with wild-type enzyme in the presence of AdoMet 
(Figure 4A). The AdoMet responsive peptide identified by hydrogen exchange MS 
reveals that in the catalytic domain mutations, P78R/K102N, as in the regulatory 
mutation, D444N, the exchange kinetics for this peptide in the absence of AdoMet mimic 
that for wild type enzyme, in the presence of AdoMet (Figure 4B).  Thus, the double 
mutant exhibits an identical conformational signature in a regulatory domain peptide that 
is seen with wild type enzyme in the presence of AdoMet or the regulatory domain 
mutant, D444N (Figure 4). To our knowledge, this is the first demonstration of mutations 
in the catalytic core that mimic the AdoMet insensitivity of a subclass of CBS1-domain 
mutations (6, 9).  
The K102N mutation exhibits only mild deficits being ~2- to 3-fold less active than 
wild type enzyme in the absence or presence of AdoMet (Table 1). The distinguishing 
kinetic feature of this mutant is that it exhibits non-Michaelis Menten kinetics when 
homocysteine is the variable substrate and the sigmoidal dependence is associated with a 
Hill coefficient of 3. This feature is also observed in the double mutant, which exhibits a 
KM for homocysteine that is comparable in value to that of wild-type enzyme but exhibits 
positive cooperativity with a Hill coefficient of 3. Thus, the change in interaction 
between subunits in the double mutant with respect to homocysteine binding can be 
ascribed to the missense mutation at the K102 locus. Interestingly, the individual single 
mutants are each less active than the double mutant indicating favorable compensatory 
changes in the linked pair that restores basal activity to wild-type levels.  
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An earlier study had reported preliminary characterization of the single and double 
mutants in E. coli cell extracts (23). Both the P78R and K102N single mutants exhibited 
fairly variable activity that were 2- to 10-fold lower than wild type enzyme, depending on 
the clone. The authors reported seeing no activity with the double mutant. These results 
are inconsistent with those reported in this study for the P78R/K102N mutant and also 
with the absence of a classical homocystinuric clinical phenotype in one of the siblings in 
whom this mutation has been described, especially since the other mutation in this 
patient, E239K, has also been reported by the same group to be associated with no 
activity in cell extracts (23). The basis of the discrepancy between the two studies is not 
known. However, it is interesting to note that other patients with nonclassical 
homocystinuria have been described who also have mutations that map to the regulatory 
domain of cystathionine β-synthase and result in AdoMet-unresponsiveness (15). These 
patients exhibit high plasma homocysteine levels in the absence of the neurological or 
connective tissue defects classically associated with homocystinuria due to cystathionine 
β-synthase deficiency. This clinical presentation is reminiscent of the male patient with 
the AdoMet-unresponsive P78R/K102N double mutation, associated with nonclassical 
homocystinuria (23). 
Computational studies have revealed that insensitivity to allosteric activation by 
AdoMet can result in hyperhomocysteinemia particularly under conditions of high 
methionine intake when the transsulfuration pathway becomes especially important in 
disposing off excess methionine and homocysteine (16). While the AdoMet-
unresponsiveness of the P78R/K102N mutation could similarly predispose patients to 
hyperhomocysteinemia, the interaction with subunits containing the second mutation 
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found in these patients, E239K, may significantly alter the phenotype of the encoded 
protein. Alternatively, the nucleotide changes associated with the double mutation could 
alter gene expression. 
Finally, although known for some time in laboratories that work on this protein, the 
oligomeric heterogeneity associated with wild-type cystathionine β-synthase has not been 
characterized primarily due to the difficulty in stably resolving the different enzyme 
forms. The P78R mutation appears to afford some stabilization of the dimer, which has 
permitted the limited characterization reported in this study. It is not known if some or all 
of the multiple oligomeric states of cystathionine β-synthase are constructed from 
monomers (or dimers) that have slightly different conformations, and therefore qualify as 
“morpheeins”, a model for allostery in which the monomer conformation dictates the 
resulting oligomeric state (28). The analysis of an uncommon allele of human 
porphobilinogen synthase allowed isolation and crystallization of a hexameric form, 
distinct from the octamer seen with wild-type enzyme and led to the morpheein concept 
(29). Elegant studies have since shown that it is the quaternary structure change rather 
than the amino acid change that underlies the differences in the kinetic properties of the 
two variants of porphobilinogen synthase (29, 30). We currently have insufficient data to 
evaluate whether or not a dynamic morpheein equilibrium is responsible for the multiple 
quaternary states of cystathionine β-synthase but note that some of the kinetic attributes 
of morpheeins viz. dependence of activity on order of substrate addition and hysteresis, 
have been observed with cystathionine β-synthase (13).  
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Chapter 4 
Redox Potentials of the Heme and CXXC Motif and their Modulation of 
Human Cystathionine β-synthase Activity 
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4.1 Abstract 
Cystathionine β-synthase (CBS) is a heme containing PLP-dependent enzyme that 
condenses serine and homocysteine to form cystathionine. CBS is the first enzyme in the 
transsulfuration pathway, commits homocysteine to cysteine synthesis, and is subject to 
complex regulation. In addition to heme, human CBS has a second putative redox-active 
center, a CXXC motif comprising the residues C272-P273-G274-C275, whose role in 
regulating enzyme activity is not known. In this study, we have developed a new assay 
for CBS that uses a non-thiol substrate analog, homoserine. We demonstrate that in 
addition to the heme, the activity of human CBS is influenced by the redox state of the 
CXXC motif. Interestingly, the activity of CBS responds reciprocally to the oxidation 
state of the two motifs, increasing when the CXXC motif is reduced while decreasing 
when the heme is reduced. To resolve this seeming paradox, we have determined the 
midpoint redox potentials of the heme in full-length human CBS and the CXXC motif 
and found them to be -356 ± 6 mV and -240 ± 4 mV respectively, versus the standard 
hydrogen electrode. The reversible formation of a disulfide bridge between C272 and 
C275 was demonstrated by mass spectrometry, which also revealed the presence of the 
sulfenic acid intermediate state of the CXXC motif. These studies suggest that the 
presence of two redox sensors in human CBS can fine tune the response of this protein to 
the ambient redox state rendering it maximally active in a potential range where the 
CXXC motif is reduced and the heme is oxidized.   
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4.2 Introduction 
Cystathionine β-synthase (CBS) is a novel pyridoxal 5´-phosphate (PLP)-dependent 
heme protein that catalyzes the condensation of serine and homocysteine to cystathionine 
(1, 2). CBS has a modular domain structure and consists of an N-terminal domain which 
houses the PLP and the heme binding sites along with a second redox active CXXC 
motif. The C-terminal domain of the protein contains a tandem repeat of CBS domains, 
CBS1 and CBS2, which are believed to be involved in the binding of the allosteric 
activator, S-adenosylmethionine (AdoMet) (3). The full-length enzyme exhibits 
oligomeric heterogeneity and exists as a mixture of tetramers and higher order oligomers 
(4, 5). Limited proteolysis of human CBS generates a more stable truncated dimeric form 
missing 143 residues from the C-terminal end and exhibits an ~4 fold higher kcat than the 
full-length enzyme (6, 7). TNFα activation of transformed human liver cells also leads to 
formation of a truncated CBS dimer demonstrating the physiological relevance of this 
form of the enzyme (8).  
CBS is located at a metabolic junction where the decision is made to conserve 
methionine by salvaging homocysteine to the methionine cycle or to commit it to 
cysteine, and it is thus subjected to complex regulation (Fig. 1). AdoMet, which signals 
methionine sufficiency, is a V-type allosteric activator and increases the specific activity 
of CBS 2- to 3-fold (9). AdoMet also stabilizes CBS, increasing the half life of the 
protein in liver (10). The C-terminal domain, to which AdoMet is presumed to bind (11), 
imposes intrasteric inhibition, which is alleviated either by its truncation or by binding of 
AdoMet (6, 12, 13). In addition to these modes of regulation, CBS is also subjected to 
redox regulation (14). Thus, under in vitro conditions, changes in the activity of CBS are 
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correlated with changes in the oxidation state of the heme with the protein being ~2-fold 
more active under oxidizing conditions. However, the role of the CXXC motif has not 
been assessed since the high homocysteine concentrations used in the in vitro assay (30 
mM) would reduce the CXXC disulfide if it existed, and mutations of the cysteines in this 
motif mimic only the reduced state of the protein (15). One rationale for redox regulation 
of CBS is that this protein, by catalyzing the committing step for cysteine synthesis via 
the transsulfuration pathway, influences the synthesis of the antioxidant, glutathione (Fig. 
1). It is estimated that ~50% of the cysteine incorporated into glutathione in liver 
originates from the transsulfuration pathway (16, 17) while the remainder is presumably 
derived from extracellular cystine via import and subsequent reduction. The role of CBS 
in provision of cysteine is evidenced by the lower cysteine concentration in brain and 
liver in a murine knockout model of hyperhomocysteinemia, heterozygous for CBS gene 
disruption (18). 
 
Fig 1.  The transsufuration pathway links homocysteine and glutathione metabolism. 
MS, BHMT and γ-CSase denote methionine synthase, betaine-homocysteine 
methyltransferase and γ-cystathionase respectively. 
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The heme in CBS is ~20Å away from the catalytic site where the PLP is bound (Fig. 
2) (15, 19). The heme resides within an N-terminal extension of ~70 amino acids, which 
is absent in the closely related yeast enzyme (20). CBS binds a single equivalent of heme 
b per monomer and H65 and C52 serve as the axial ligands in both the ferric and ferrous 
states (15, 19). The heme is not essential for catalysis as evidenced by the retention of 
~40 percent of wild-type activity in a hemeless variant of human CBS (21). Despite the 
substantial distance from the active site, changes in the heme environment elicited by 
binding of exogenous ligands to the heme, or a change in the heme iron’s spin or 
oxidation state, affect CBS activity, consistent with a regulatory role for this cofactor (22-
24). Ferrous CBS can bind small gaseous molecules like CO and NO (24), a property 
shared by heme sensor proteins viz. FixL, CooA, and HemeAT (25). Based on these 
characteristics, CBS has been postulated to be a redox-regulated heme sensor protein 
(15).  
 
Fig 2. A. Structure of the truncated dimeric form of CBS showing the locations of heme 
(red), PLP (blue) and the cysteines in the CXXC motif (yellow). B. The relative positions 
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of the PLP, heme and the CXXC motif in the crystal structure of CBS-ΔC143. The 
numbers represent approximate distances in Å. 
 
 
 
The CXXC motif in CBS is approximately equidistant from the heme and PLP 
centers being ~20Å away from each (Fig. 2). The CXXC motif is commonly found in the 
active sites of the thioredoxin family of proteins and is usually involved in thiol-disulfide 
exchange reactions (26). In human CBS, residues C272-P273-G274-C275 comprise the 
CXXC motif, which is conserved in several organisms but is missing in the yeast and 
Dictyostelium enzymes (1). It is interesting to note that the CXXC motif in thioredoxin is 
also comprised of the same sequence of residues i.e., CPGC (26). Two crystal structures 
of the truncated dimer of CBS have been reported and the CXXC motif is in the 
disulfide-linked state in one and in the dithiol state in the other (14, 19). The crystal 
structures reveal that the CXXC motif is accessible to small molecule reductants, e.g. 
dithiothreitol, which was used for crystallization of the dithiol form of the enzyme, and 
suggests that this motif may be redox active in CBS.      
In this study, we have characterized the two redox centers in CBS, the heme and the 
CXXC motif, as a first step towards evaluating their potential for redox regulation in the 
intracellular milieu. To determine the effect, if any, of the CXXC redox state on CBS 
activity, we have developed a new assay in which a nonthiol substrate, homoserine, 
substitutes for homocysteine. We have determined the midpoint potentials for the heme 
and the CXXC motif in human CBS. Our results suggest that the presence of two redox 
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sensitive motifs in CBS may allow for fine-tuning of the redox responsiveness of the 
enzyme to the ambient potential. 
 
 
4.3 Materials and methods 
Materials-Serine, Isopropyl β-D-1-thiogalactopyranoside (IPTG), iodoacetic acid (IAA), 
dithiotreitol (DTT), methyl viologen, benzyl viologen, anthroquinone 2-sulfonic acid, 
trypsin and Glu-C (V8-E) were purchased from Sigma. [14C]-Serine (158 mCi/mmol) was 
purchased from Amersham and GST Sepharose from Pharmacia. Thrombin was 
purchased from GenTrac Inc., Middleton, WI. Complete tablets (protease cocktail 
inhibitors) were purchased from Roche Diagnostics (Mannheim, Germany). Rapigest was 
purchased from Waters (Milford, MA). Mal-PEG 5 kD was purchased from Laysan Bio 
Inc (Alabama). Mal-PEG 5 kD is usually contaminated with lower molecular weight 
components that cause smearing during polyacrylamide gel electrophoresis. To avoid this 
problem, the lower molecular weight contaminants were separated from Mal-PEG 5 kD 
using a PD-10 desalting column (from Amersham) and 50 mM Tris-HCl buffer, pH 8, for 
isocratic elution. All the other reagents were used without further purification. 
Purification of Full-Length CBS and the Truncated Dimer-The truncated dimer, CBS-
ΔC143, lacking the C-terminal 143 amino acids, and the full-length wild-type enzyme 
were expressed and purified from Escherichia coli BL21 cells (Invitrogen) as described 
previously (14) except that reducing agents were omitted from all the steps of the 
purification.  
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Homoserine Assay for CBS- This assay is a modification of the standard assay described 
previously (14), where the natural substrate, L-homocysteine, is replaced by the nonthiol 
derivative, L-homoserine (Fig. 3). The enzyme activity was assayed under aerobic 
conditions using 30 mM [14C]-serine and 10 mM L-homoserine in the presence or 
absence of 20 mM DTT or 20 mM glutathione. The amount of enzyme used in the assay 
was 1 µg for the truncated dimer and 5 μg for full-length CBS. One unit of enzyme 
activity represents the amount needed for formation of 1 µmol of product•h-1 at 37 °C. 
Protein concentration was determined by the Bradford method using bovine serum 
albumin as a standard. 
 
Figure 3. Schematic representation of the condensation reaction between serine and 
homoserine or the alternate substrate, homoserine, catalyzed by CBS. 
 
 
 
Determination of the Redox State of the CXXC Motif by Mass Spectrometry (MS)-
CBS-ΔC143 (50 µg) in the reduced (with 50 mM DTT) and oxidized (lacking DTT) 
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states was treated with IAA (20 mM) for 1 h at room temperature in the dark. Excess 
DTT was removed from the reduced sample preceding the alkylation step, by extensive 
washing with 10 mM ammonium bicarbonate buffer, pH 8, containing 8 M urea, using a 
YM-30 Centricon concentrator (Millipore). The alkylation reaction was quenched by 
addition of excess DTT and the samples were diluted 10-fold and washed with 10 mM 
ammonium bicarbonate buffer, pH 8 using a YM-30 Centricon concentrator. Proteolytic 
digestion was then performed using Glu-C or trypsin at an enzyme to substrate ratio of 
1:20 (wt/wt). Rapigest, a mild detergent, was used as per the vendor’s instructions, to 
improve sequence coverage. The digestion reaction was carried out for 30 h at 37°C and 
the peptides were separated by HPLC on a C18 column (PepMap100, 75 µm x 15 cm, 3-
µm 100 Å, LC Packings, Sunnyvale, CA) using a gradient of acetonitrile and water. The 
solvents used for separation were: A (water with 0.3% formic acid) and B (acetonitrile 
containing 0.3% formic acid). The gradient was 10-35% solvent B over 20 min at a flow 
rate of 40 µl/min. The masses of individual peptides were determined by ESI-MS on a 
Quadrupole time-of-flight mass spectrometer (Applied Biosystems). Peptides were 
identified by tandem ESI-MS/MS sequencing.  
Spectroelectrochemistry of Full-length CBS-Potentiometric measurements were 
performed using a two-electrode single compartment spectroelectrochemical cell 
containing a gold foil working electrode and a silver/silver chloride reference electrode 
(27). The experiments were performed under a nitrogen atmosphere in a Belle 
Technology glove box and in a vacuum atmosphere chamber, with <1 ppm oxygen. 
Potential measurements are reported relative to the normal hydrogen electrode and were 
determined in the reductive and oxidative directions. The experiments were carried out at 
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25°C in 50 mM potassium phosphate buffer, pH 7.2. The potentials were determined in 
the reductive direction by titrating the enzyme with sodium dithionite (added in 
increments of 2 μM). The enzyme concentration was maintained at ~10 μM in a 4 ml 
cell. Methyl viologen (10-20 μM), benzyl viologen (10-20μM) and anthraquinone 2-
sulfonic acid (10 μM) were used as the mediator dyes in the potentiometric experiments. 
The potentials for the indicator dyes are as follows: methyl viologen (Eo = -440 mV, pH 
7.5), benzyl viologen (Eo = -360 mV, pH 7.5) and anthraquinone 2-sulfonic acid (Eo = -
225 mV, pH 7.0). The system was deemed to be at equilibrium in these experiments 
when the measured potential change was less than 1 mV in 5 min, and this was typically 
achieved within 45 min following addition of dithionite. In the oxidative direction, 5 µM 
aliquots of potassium ferricyanide were added to CBS, previously reduced with 75 μM 
dithionite. The UV-visible spectra in each experiment were recorded from 300 to 800 nm 
on a Cary 100 spectrophotometer. The absorbances at 428 nm and 449 nm were used to 
estimate the amount of oxidized and reduced species, respectively. The final spectra were 
obtained by subtracting the blank, i.e. spectra of the mediator dyes in the same buffer and 
at the same potential from the spectrum of the enzyme. The measured potential was fit to 
the Nernst equation (equation 1), where the concentration of the reduced species at a 
given potential was obtained by the difference in absorbance at 428 nm or 449 nm from 
the spectrum of the fully oxidized form (in the reductive direction). 
  0.059  [ox] 
 E = E + ——— log —— eq. 1 
  n  [red] 
 
Alkylation with Mal-PEG and Determination of the Midpoint Potential of the CXXC 
Motif-Samples of CBS-ΔC143 (50 μg each) in 50 mM Tris-HCl, pH 8, were incubated 
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with various ratios of oxidized to reduced DTT for 2.5 h at 37°C. Thereafter, samples 
were precipitated with an equal volume of 20% TCA and centrifuged at 13,500 x g for 20 
min. The precipitated samples were washed three times with 1 ml of chilled acetone and 
then dried. The precipitates were resolubilized with 50 mM Tris-HCl, pH 8, 3% SDS, 1 
mM EDTA and 5 mM Mal-PEG. The samples were incubated in this buffer for 10 min at 
37°C. The reaction was quenched with excess DTT and centrifuged at 13,500 x g for 20 
min to remove any insoluble protein. The cleared samples were then washed extensively 
with buffer free of Mal-PEG using YM-30 Centricons (Millipore) to remove excess 
alkylating reagent. Thereafter, the samples were mixed with gel loading buffer and 
resolved on a 6% polyacrylamide gel using electrophoresis at 30 mA current. The protein 
bands were stained with Coomassie blue and the band intensities were estimated with the 
imaging software installed in the Gel-Doc instrument (BioRad). The midpoint potential 
was -240 ± 4 mV. 
Alkylation with Mal-PEG and Determination of the Midpoint Potential of the CXXC 
Motif-Samples of CBS-ΔC143 (50 μg each) in 50 mM Tris-HCl, pH 8, were incubated 
with various ratios of oxidized to reduced DTT for 2.5 h at 37°C. Thereafter, samples 
were precipitated with an equal volume of 20% TCA and centrifuged at 13,500 x g for 20 
min. The precipitated samples were washed three times with 1 ml of chilled acetone and 
then dried. The precipitates were resolubilized with 50 mM Tris-HCl, pH 8, 3% SDS, 1 
mM EDTA and 5 mM Mal-PEG. The samples were incubated in this buffer for 10 min at 
37°C. The reaction was quenched with excess DTT and centrifuged at 13,500 x g for 20 
min to remove any insoluble protein. The cleared samples were then washed extensively 
with buffer free of Mal-PEG using YM-30 Centricons (Millipore) to remove excess 
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alkylating reagent. Thereafter, the samples were mixed with gel loading buffer and 
resolved on a 6% polyacrylamide gel using electrophoresis at 30 mA current. The protein 
bands were stained with coomassie blue and the band intensities were estimated with the 
imaging software installed in the Gel-Doc instrument (BioRad). The midpoint potential 
was calculated using equation 2, where Eo´ = -250 mV, the standard reduction potential 
for DTT at pH 8 and 37°C, R is the universal gas constant, T is the temperature in  
  RT  [DTTred] 
 E0 = E0’ + —— ln————— eq. 2 
  nF  [DTTox] 
degrees Kelvin, F is the Faraday constant, n is the number of electrons transferred and Eo 
is the redox potential under experimental conditions.  
 
 
4.4 Results 
Purification and redox-dependent CBS activity-The truncated dimer (CBS-ΔC143), and 
full-length wild-type CBS were obtained in at least 95% purity as determined by SDS-
PAGE analysis and by a ratio of ~1 for the 280:428 nm absorbance (not shown). The 
specific activity of the full-length enzyme and the truncated dimer in the presence of DTT 
and homoserine, are 18.3 ± 1.0 and 350 ± 13 µmol•h-1•mg-1 protein compared to 350 ±40 
and 600 ±70 µmol•h-1•mg-1 protein respectively in the standard assay with homocysteine. 
In the absence of DTT, the activity of the truncated dimer and the full-length CBS were 
4.6- and 1.6-fold lower respectively (Table 1). Glutathione (20 mM) was less effective at 
reducing CBS than DTT at least under the assay conditions, and a modest 1.3 fold 
increase in specific activity was observed with the truncated dimer while no effect was 
detected with the full-length enzyme, probably due to the low activity associated with the 
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full-length enzyme in the homoserine assay. Since the oxidized state of the heme iron in 
CBS is unaffected by DTT as evidenced by the presence of a ferric Soret peak at 428 nm 
(14), these results suggest that the enhancement in activity upon reduction, is due to a 
change in the redox state of the cysteines. 
Due to the low specific activity of full-length CBS seen in the homoserine assay, 
further kinetic characterization was performed only with the truncated enzyme. The 
KMHser and KMSer for the truncated dimer are 1.3 ± 0.2 mM and 1.6 ± 0.2 mM, 
respectively (Table 1). These values are similar to the kinetic parameters reported earlier 
for the full-length enzyme in the standard assay (KMser = 2.0 mM KMHcy = 5 mM) (7, 28). 
In contrast, the KM values for serine and homocysteine reported for the truncated dimer in 
the standard assay are significantly higher (KMser =18 mM and KMHcys = 9.7 mM) (7). The 
basis for these differences is not known. 
 
Table 1. Kinetic parameters for the full length and the truncated CBS using homoserine 
and serine under standard assay conditions 
aKM is in units of mM 
bSpecific activity in units of μmoles of cystathionine formed h-1mg-1 of protein and was 
determined in the presence of AdoMet for full-length CBS 
cNot determined 
Kma  Specific Activityb 
CBS 
Homoserine Serine  -DTT +DTT Fold Activation 
Full-length  N.Dc  N.Dc  11.4 ± 0.8 18.3 ± 1.0 1.6 
CBS-ΔC143  1.3 ± 0.2 1.6 ± 0.2  76.4 ± 5.0  350 ±13.0 4.5 
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Detection of a disulfide bond in the CBS CXXC motif by mass spectrometry-Since the 
truncated variant of CBS does not exhibit the highly heterogenous oligomeric and 
aggregation states seen with the full-length enzyme, MS analysis for monitoring the 
redox state of the CXXC motif was conducted on this form of the enzyme. Generation of 
CBS-ΔC143 leads to deletion of only one of the eleven cysteines present in the full-
length enzyme, C431, which is reported to be solvent accessible (4). Alkylation of CBS-
ΔC143 with IAA in the presence or absence of DTT and subsequent digestion with 
trypsin or Glu-C led to the identification of all nine peptides in which the ten cysteine 
residues in the truncated dimer reside. The masses of the individual peptides were 
determined by ESI TOF MS (Table 2) and MS/MS fragmentation pattern of each peptide 
was used to confirm its identity. One peptide carried the two cysteines in the CXXC 
motif. Under reducing and non-reducing conditions, the masses of all but one peptide 
exhibited modification of the resident cysteine by a single IAA residue i.e., an addition of 
58 Da. The exception was the peptide, KC272PGC275RIIGVDPE, which exhibited a 
monoisotopic mass of 1501.69 (corresponding to the addition of two IAA residues), 
under reducing conditions and a monoisotopic mass of 1383.66 (corresponding to the 
presence of an intramolecular disulfide bridge) under air oxidized conditions. The +3 
charge states of the two forms of the peptide are shown in Fig. 4 with m/z values of 
501.57 and 462.22 for the reduced and oxidized states respectively. 
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Table 2. Comparison of the expected and observed monoisotopic masses of CBS 
peptide fragments with IAA–modified cysteines  
 
ain Da 
bSample was modified with IAA without reduction 
cSample was reduced with DTT before IAA modification 
 
Molecular Weighta  
Number of IAA 
Modifications 
Cysteine 
Residue 
Peptide Covering the Cysteine 
Observed Calculated  -DTTb +DTTc
52 CTWLGRPASESPHHHTAPAK 2368.05 2368.11  1 1 
15 VGPTGCPHRSGPHSAKGSLE 2030.92 2030.96  1 1 
103 FGLKCELLAK 1178.60 1178.64  1 1 
109 CEFFNAGGSVK 1215.45 1215.52  1 1 
346 MLIAQEGLLCGGSAGSTVAVAVK 2232.09 2232.15  1 1 
370 CVVILPDSVR 1157.57 1157.61  1 1 
165 CIIVMPEK 989.42 989.49  1 1 
272, 275 KCPGCRIIGVDPE 1501.63 1501.69  0 2 
244 ILQQCDGKLDMLVASVGTGGTITGIARKL 3272.71 3272.75  1 1 
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Figure 4. A. Mass analysis of the KC272PGC275RIIGVDPE peptide obtained by two 
IAA modifications (under reducing conditions). The charge state is +3 and yields an Mr 
of 1501.69 and an m/z value of 501.57. B. Mass analysis of the KC272PGC275RIIGVDPE 
peptide containing a disulfide bridge between C272 and C275 (under air oxidized 
conditions). The charge state is +3 and yields an Mr of 1383.66 and an m/z value of 
462.2. 
 
 
 
Evidence for the presence of a sulfenic acid in the CXXC motif-MS analysis of the 
peptides generated under air oxidized conditions revealed a species with a +4 charge state 
corresponding to an m/Z value of 365.937 as shown in Fig. 5. The monoisotopic mass of 
this peptide is 1459.72 and represents the presence of a 59 Da and a 17 Da modification 
corresponding to the addition of a single IAA and a hydroxyl group respectively, to 
1383.66, the mass of the KC272PGC275RIIGVDPE peptide bearing a disulfide bond. The 
presence of a hydroxyl group is consistent with the formation of a sulfenic acid 
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modification representing an intermediate between the dithiol and disulfide states, in 
which one cysteine is oxidized to sulfenic acid and the other is reduced.  
 
Figure 5. Mass analysis of the KC272PGC275RIIGVDPE peptide bearing a sulfenic acid 
derivative on one of the cysteines in the CXXC motif. The charge state is +4 and yields 
an Mr of 1459.66 and an m/z value of 365.9. 
 
 
 
Determination of the midpoint potential of the CXXC center in CBS-Although Mal-PEG 5 
kD has a molecular mass of 5 kD it causes an ~20 kD shift per modified thiol in the 
electrophoretic mobility of polypeptides under denaturing conditions (29). When CBS-
ΔC143 was alkylated with Mal-PEG at varying ratios of oxidized to reduced DTT, two 
bands of 245 and 205 kD molecular mass were observed (Fig. 6). The band with a 
molecular mass of 245 kD represents the addition of 200 kD to the mass of CBS-ΔC143 
(45 kD) and corresponds to the presence of ten Mal-PEG moieties. The lower protein 
band at ~205 kD corresponds to the oxidized population of CBS bearing eight Mal-PEG 
96 
modifications, consistent with the presence of two cysteines in a disulfide linkage. The 
intensity of the higher molecular mass band decreased with a corresponding increase in 
the intensity of the lower band as the ratio of reduced to oxidized DTT decreased (Fig. 6). 
Quantitative analysis of the band intensities as a function of the redox potential poised by 
varying ratios of oxidized to reduced DTT, yielded an estimated midpoint potential of -
240 ± 4 mV for the CXXC motif in CBS.  
 
Figure 6: Determination of the midpoint potential of the CXXC motif by alkylation 
with Mal-PEG. A. Distribution of the upper and lower bands representing the reduced 
and oxidized forms of CBS-ΔC143 respectively by SDS PAGE analysis. The upper band 
results from two extra MAL-PEG modifications versus the population representing the 
lower band. The relative intensities of the upper and lower bands depend on the ratio of 
DTTred/DTTox. (B) Quantitative analysis of the data shown in A. The chart at the bottom 
indicates the relative amounts of oxidized and reduced DTT in each reaction mixture. (C) 
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Nernst analysis of the CXXC redox state at varying potentials poised by changing the 
relative proportions of reduced and oxidized DTT.  
 
 
 
Determination of the midpoint potential of the heme center in full-length CBS-
Spectroelectrochemical titrations were performed to estimate the redox potential of the 
heme in full-length CBS by following the intensity of the heme Soret peak as described 
under Methods. From this analysis, the average midpoint potential for the heme in wild 
type full-length CBS was determined to be -356 ± 6 mV for titrations in the reductive 
(average = -353 ± 6 mV) and oxidative directions (-358 ± 5 mV). Fig. 7 shows a 
representative potentiometric titration of the heme in full-length CBS. The presence of 
100 µM AdoMet, an allosteric activator of CBS, during the titration had no effect on the 
heme redox potential. 
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Figure 7. Redox potential determination for the heme in full-length CBS. The 
potentiometric titration was performed at 25˚C in the presence of 20 μM benzyl viologen, 
20 μM methyl viologen, 8 μM wild type CBS with 2 μM incremental addition of sodium 
dithionite. The spectra are shown after mediator dye subtraction. The 428 nm ferric 
species converted to the 449 nm ferrous species as sodium dithionite was added. Inset. 
Nernst analysis of this data yielded a redox potential of -352 ± 4 mV for the heme with a 
slope of 73 ± 7.5 mV.(Madzelan, P Banerjee R) 
 
 
 
4.5 Discussion 
CBS catalyzes the first step in the transsulfuration pathway, which converts 
homocysteine to cysteine via the intermediate formation of cystathionine (Fig. 1). The 
quantitative significance of this pathway for provision of intracellular cysteine, needed 
for glutathione synthesis, links the metabolism of homocysteine directly to cellular redox 
homeostasis (16, 17). Additionally, the activity of CBS contributes to determining the 
balance between the transsulfuration and transmethylation pathways for clearing 
intracellular homocysteine and thereby determining the fate of intracellular sulfur in 
mammals. As expected, this critical junction in sulfur metabolism is subject to multiple 
layers of regulation including regulation by AdoMet and by the ambient redox state (1).  
Cell culture studies have revealed that under conditions of oxidative stress, the flux of 
homocysteine through the transsulfuration pathway is increased (17). The physiological 
rationale for this response is that it represents an auto corrective reaction that, by 
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increasing synthesis of cysteine stimulates synthesis of glutathione, thereby replenishing 
the antioxidant pool, which is depleted under oxidizing conditions. The mechanism of up-
regulation of the transsulfuration flux is however, not known. Studies with purified 
recombinant human CBS have revealed that the enzyme is approximately two-fold less 
active when low potential reductants viz. titanium citrate or dithionite are added to the 
standard assay mixture (14). Furthermore, this change in activity is correlated with a 
change in the redox state of the heme from the ferric to the ferrous state (14) and is 
unaffected by mutation of either cysteine in the CXXC motif (15). These observations 
support our earlier conclusion that under the conditions of the in vitro assay, the heme 
rather than the CXXC motif in CBS, is the redox sensor (15). However, the role of the 
CXXC motif in redox regulation of CBS cannot be assessed in this assay for the 
following reason. One of the substrates of CBS, homocysteine, is itself a thiol and, at the 
high concentrations that it is present in the standard reaction mixture (30 mM), would 
reduce the CXXC disulfide. Hence, under the standard assay conditions, the CXXC motif 
is in the reduced state, and only redox regulation by the heme can be interrogated. 
Mutation of the cysteines in the CXXC motif mimics the reduced dithiol state of this 
motif, and the resulting mutants are expected to retain heme-dependent redox sensitivity, 
as reported (15). Hence, the influence of the CXXC redox state on the activity of CBS 
has not been previously addressed and, in the absence of the values for the midpoint 
potentials for the two redox centers in CBS, their physiological relevance to redox 
responsiveness, has not been evaluated. 
To address these gaps in our understanding of the redox regulation of CBS, we have 
developed a new assay for the enzyme that uses the hydroxo-derivative of homocysteine, 
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homoserine (Fig. 3). Despite the significant difference in the pKa of the thiol group in 
homocysteine (~10.8) versus homoserine (~15), only a 19-fold lower activity is seen with 
the full-length enzyme when homoserine replaces homocysteine in the assay (18.3 ± 1.0 
versus 350 ± 40 µmol•h-1•mg protein-1). This suggests that deprotonation of 
homocysteine for the β-replacement reaction, is not completely rate limiting. With the 
truncated dimeric CBS, an even smaller 1.7-fold difference is observed between the two 
substrates (350 ± 13 versus 600 ±70 µmol•h-1•mg protein-1). Both forms of the enzyme 
however exhibit higher activity in the homoserine assay in the presence of DTT, 
indicating that the dithiol form of the CXXC motif in CBS is associated with more active 
enzyme. 
MS analysis was employed to verify the difference in the oxidation state of the 
CXXC motif suggested by the difference in the enzyme activity assays in the presence 
and absence of DTT. A combination of trypsin and Glu-C resulted in the recovery of all 
nine peptides harboring the ten cysteine residues in the truncated form of CBS, and 
confirmed the presence of a disulfide bond in the CXXC motif in the protein as isolated 
and its reduction in DTT-treated samples (Table 2 and Fig. 4).  
Reversible cysteine-targeted oxidative modifications such as formation of 
intramolecular disulfides, is a common strategy for regulating proteins under oxidative 
stress conditions (30). An example of a PLP-dependent enzyme that is subject to such 
regulation is human mitochondrial branched chain aminotransferase (31). The latter, like 
CBS, contains a regulatory CXXC motif involving cysteines 315 and 318. In the C318A 
mutant of the branched chain aminotransferase, C315 was shown to form a sulfenic acid 
intermediate, suggesting that this is the reactive cysteine that is initially oxidized during 
101 
formation of the disulfide bond. We also detected a sulfenic acid intermediate in CBS by 
mass spectrometry (Fig. 5). In the protein as isolated, this species is present at low 
abundance as suggested by the relatively low intensity associated with this signal, which 
precluded assignment by MS/MS analysis of the particular cysteine in the CXXC motif 
that is oxidized to sulfenic acid. The instability of the previously reported C272A or 
C275A mutants of CBS (15) has similarly limited efforts to identify the reactive (versus 
resolving) cysteine in the CXXC motif.  
Disulfide bonds have traditionally been considered to be either catalytic or structural 
in function. There is however growing recognition of a third class of disulfides, the 
allosteric disulfide bonds, which are capable of controlling protein function by triggering 
a conformational change. A recent analysis of protein crystal structures has revealed 
differences in disulfide bond geometry and in disulfide strain energy between structural, 
catalytic and allosteric disulfide bonds (32). Disulfides with low dihedral strain energies, 
typically between 9.7-10.4 kJ mol-1 are assigned to be structural in nature whereas those 
with higher values are assigned as either catalytic or allosteric in function (≥ 12 kJ mol-1), 
with the catalytic disulfides typically having higher values than the allosteric ones (32). 
Based on this analysis, the C272-C275 disulfide bond in CBS is classified as a -
/+RHHook catalytic bond of the type seen in oxidoreductases (e.g. thioredoxin) and 
isomerases (e.g. protein disulfide isomerase) rather than an allosteric disulfide bond, 
which have the –RHStaple configuration (32). The estimated dihedral strain energy of the 
disulfide bond in the structure of truncated CBS (PDB 1JBQ) is 15.95 kJ mol-1, which 
also places it in the category of catalytic disulfides.  However, given the distance between 
the C272-C275 bond and the active site (Fig. 2), it appears unlikely that these residues 
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play a catalytic role, nor is this warranted based on the PLP-dependent β-replacement 
chemistry of the reaction. In addition, mutation of the cysteines in the CXXC motif 
results in retention of enzyme activity (15), excluding an essential role for these residues 
in catalysis. It is possible however that the CXXC motif in CBS may be involved in 
interactions with and/or regulation of other proteins. It is important to note however that 
while the CXXC motif appears to be relatively surface exposed in the structures of the 
truncated CBS dimer (15, 19), its accessibility in the full-length protein is not known.  
The CXXC motif in CBS sequences is generally correlated with the presence of the 
putative heme ligands and suggests that they may both function in a regulatory capacity 
(1). In fact, the eleven cysteine residues found in human CBS are highly conserved across 
other mammalian CBSs. In the native full-length human protein, only two cysteines are 
reported to be readily solvent accessible, C15 in the heme domain and C431 in the 
regulatory domain (4). However, the highly heterogeneous oligomeric state of purified 
recombinant human CBS, even in the presence of DTT, substrates or AdoMet 
(unpublished observations), limits such analysis. 
The opposing effects of the oxidation states of the two redox centers on the activity of 
CBS, i.e. activation by reduction of the disulfide and oxidation of the heme, seems at first 
glance, to be paradoxical. However, inspection of the predicted dependence of CBS 
activity on the ambient redox potential (Fig 8), reveals that the presence of these two 
centers can fine-tune its responsiveness to redox changes. The cytoplasmic redox 
potential is poised by the glutathione, NADPH, dihydrolipoamide and thioredoxin redox 
couples. In mammalian cells, this value has been estimated to be ~-315 to -325 mV (33). 
The thiol/disulfide redox couple in CBS has a midpoint potential of -240 mV and under 
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physiological conditions the CXXC motif is likely to be predominantly reduced. In 
contrast, the heme has a lower midpoint potential of -356 mV, which is similar to values 
reported for other heme-thiolate proteins such as cytochrome P450 (-360 mV) (34), nitric 
oxide synthase (-347 mV) (35), and CooA (-320 mV) (36). We note that we have also 
determined the redox potential of the heme in the truncated dimeric form of CBS and 
found it to be -287 ± 2 mV (37).  The difference in redox potential from the value 
measured for the full-length enzyme in this study, likely derives from changes in the 
heme microenvironment and/or heme solvent exposure between the two enzyme forms. 
The heme in full-length CBS is expected to exist as a mixture of the ferric and ferrous 
states under physiological conditions. Under oxidative stress conditions, an increase in 
the proportion of the oxidized heme would be primarily responsible for an increase in 
CBS activity (Fig. 8). 
 
Figure 8. Schematic representation of the relative change in CBS activity with redox 
potential. 
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We note however, that varying estimates for the ambient cytoplasmic redox potential 
have been reported in the literature. Based on the ratio of reduced to oxidized glutathione, 
values ranging from -200 to -240 mV have been reported (38, 39). A similar value for the 
intracellular potential in E. coli (-259 mV) has been reported using a green fluorescent 
protein-based sensor responsive to the glutathione/glutathione disulfide redox couple 
(40).  These higher values predict a different distribution of the oxidized and reduced 
forms of the heme and CXXC centers under normoxic conditions and activation of CBS 
would be expected under conditions that shift the redox potential to be more reducing 
rather than oxidizing (Fig. 8), which is not observed in mammalian cells (17).  
Another example of a protein whose activity is modulated both by the oxidation state 
of its heme and by an intramolecular disulfide/dithol equilibrium is neuroglobin (41). The 
heme in neuroglobin is hexacoordinate with bis-histidine axial ligands. Binding of 
oxygen to the heme therefore depends on the histidine dissociation rate as well as the 
relative association rates of oxygen and the competing distal histidine ligand. Reduction 
of the disulfide bond in neuroglobin results in a significant decrease in oxygen affinity, 
which in turn results from a decrease in the dissociation rate of the histidine. It is not 
known to what extent the redox state of the CXXC motif in CBS influences the reactivity 
of the heme to exogenous ligands. 
The thiol versus disulfide state of a protein can have other functional consequences. 
For instance, the nuclear localization of the redox sensitive YAP1 transcription factor is 
triggered by reduction of a regulatory disulfide, which exposes the nuclear localization 
signal (42). We have recently reported that CBS is a target of sumoylation and that it 
localizes to the nucleus in addition to its well known cytoplasmic residence (43). The role 
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of CBS inside the nucleus or the mechanism of its import into this compartment is not 
known. It is also not known whether the redox state of the CXXC motif has any influence 
on the nuclear function and/or localization of CBS.  
In summary, we report that in addition to the oxidation state of the heme, the redox 
state of the CXXC motif potentially serves as another switch for fine-tuning the redox 
responsiveness of the enzyme. The midpoint potentials of the heme and CXXC centers in 
human CBS reported in this study allows prediction of how the activity of this enzyme 
may be modulated by changes in the ambient intracellular redox potential.  
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Chapter 5 
Summary and future directions 
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Summary 
CBS is the first enzyme in the transsulfuration pathway which commits homocysteine 
to cysteine synthesis and is subject to complex regulation. Although it was known that 
CBS undergoes intrasteric and allosteric regulation, insights into the structural basis of 
this regulation were obtained for the first time in this study. In addition, this thesis 
elucidated the role of the CXXC motif and established its redox-dependent role in 
regulating CBS. 
The first part of this dissertation sheds light on localizing conformational changes 
associated with allosteric and intrasteric regulation of human CBS. CBS functions at a 
critical metabolic junction where the decision to conserve homocysteine via the 
methionine cycle or to commit it to transsulfuration and therefore cysteine synthesis is 
made. It is thus expected that the enzyme is tightly regulated. This includes intrasteric 
inhibition imposed by the C-terminal domain and allosteric regulation by AdoMet. 
Interestingly, a subset of pathogenic CBS mutations have been reported that map to the 
regulatory domain, display a higher level of basal activity but are nonresponsive to 
allosteric activation. The structural basis for this apparently paradoxical phenotype has 
been investigated for the first time in this study. 
Kinetic studies indicate that the wild-type enzyme equilibrates between at least two 
conformations, the “basal” state and the “activated state” that is induced by AdoMet. We 
employed H/D exchange MS to localize focal conformational changes in wild-type CBS 
induced by AdoMet, to a peptide which spans residues 511-531 in the regulatory domain. 
We surmise that this region becomes more exposed to solvent in the presence of AdoMet. 
Interestingly this “activated” conformation is mimicked by the pathogenic mutation 
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D444N, which has a kcat similar to that of the “activated” state of the wild-type enzyme 
but is nonresponsive to AdoMet. Interestingly the 511-531 peptide is located in the C-
terminal module of the enzyme where AdoMet is predicted to bind. This domain 
comprises a tandem repeat of two CBS domains. Since the structure of the full-length 
CBS is unavailable, we have generated a homology modeled structure of the C-terminal 
regulatory domain using the coordinates for a CBS domain protein from 
M.thermoautotrophicus. The sensitivity of the 511-531 peptide could be consequential of 
its proximity to the binding site for AdoMet and/or its location on the pathway of 
allosteric signal transduction. 
The kinetics of hydrogen exchange further revealed two surfaces represented by 
peptides 356-370 and 371-385, which are sensitive to deletion of the regulatory domain. 
Interestingly several pathogenic mutations including R369C/H and K384N/E have been 
reported in these two stretches. We have employed the H/D exchange MS data in 
conjunction with the reported properties of CBS guide our docking model for the full-
length enzyme. We reasoned, based on biochemical data that the 356-370 peptide is 
involved in making direct contact with the regulatory domain and hence maps on to the 
regulatory-catalytic interface. The 371-385 peptide on the other hand is located at the 
bottom of a cavity and leads to a short helix leading to a loop representing the C-terminus 
of the catalytic domain. We employed the docked model of the full-length dimeric CBS 
to generate a model of the full-length tetramer. in the absence of a full-length crystal 
structure, this model has been used to rationalize the pathological basis of several patient 
mutants.  
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The second part of this dissertation describes the characterization of the linked 
P78R/K102N pathogenic mutation in the catalytic core of CBS. The mutants P78R and 
K102N were created to study the contributions of each locus to the linked mutant. The 
P78R mutant which existed as a mixture of a full-length dimeric form and higher order 
oligomers, allowed for the first time limited kinetic characterization of the full-length 
dimeric state of CBS. Upon activation at 4°C, the higher order oligomers converted to the 
apparently more stable full-length dimer exhibiting a different specific activity. These 
results suggest the possibility that CBS may distribute itself into various oligomeric states 
under specific cellular conditions and/or in different compartments and that this may 
represent yet another mode of regulation. 
The unresponsiveness of the P78R/K102N mutant towards AdoMet makes it the first 
catalytic core mutation reported with such a phenotype. H/D exchange studies conformed 
that the double mutant exhibited a similar conformation as seen in the D444N mutant 
indicating that it is also locked in kinetically “activated” state. The finding of AdoMet 
nonresponsive mutants in both the catalytic as well as the regulatory domains is 
consistent with the interactions between the two domains.  
The third and the final portion of this thesis focused on redox regulation of CBS. For 
the first time it was established that the CXXC motif in CBS is redox active. The change 
in the redox state of the CXXC motif is communicated to the catalytic center which 
causes an increase in activity (4.5-fold in the truncated dimer and 1.6-fold in the full-
length enzyme), upon reduction of the disulfide to a dithiol. This modulation in the 
activity with respect to the redox changes at the CXXC center is opposite to that seen at 
the heme center where a reduction of the iron actually decreased the activity by ~2 fold. 
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The reciprocal redox dependency associated with the two centers would represent a 
mechanism for fine tuning the global redox regulation of CBS. The midpoint potentials of 
the heme (-356 ± 6mV) and the CXXC center (-240 ± 4mV) reported in this study allows 
prediction of how CBS activity may be modulated by changes in the ambient redox 
potential. 
 
 
Future directions 
The physiological relevance of the existence of CBS in various oligomeric forms is 
yet to be established. Characterization of various mutants have revealed the existence of a 
mixture of higher order oligomers (including tetramers) and full-length dimers such as 
seen in the P78R mutant as detected in this thesis. It would be interesting to study the 
oligomeric distribution of CBS in vivo, to assess whether the sampling of different 
oligomeric states is seen and if it changes under different conditions i.e. oxidative stress 
or methionine restriction. Investigations to detect the oligomeric state of CBS in the 
different cellular compartments where it localizes (i.e. in nucleus and the cytoplasm), 
may further shed light on its diverse functioning. 
An important area that can also be further developed, is redox regulation of CBS. In 
vitro studies have identified the redox regulatory centers in CBS. As a next step, the 
redox status of the enzyme will have to be established in vivo. It would be interesting to 
study the redox status of this enzyme both in the cytoplasm and nucleus. Investigations 
should be concluded to assess if localization of CBS and/or its function in the nucleus is 
redox dependent.  
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Although a change in the redox state in the CXXC motif in CBS has been shown to 
be communicated to the active site, the mechanism of this transmission is yet to be 
investigated. Studies aimed at mapping conformational changes if any, or interaction with 
potential redox partners via the CXXC center will address important gaps in our 
knowledge of redox regulation of CBS in vivo. 
 
 
